HOME     SUBSCRIBERS     TRADE     PRODUCTS & SERVICES    
About Sharenet
Enter any share name or code:    

13-Oct-2017
(Official Notice)
Shareholders are advised that the the UK Competition and Markets Authority (?CMA?) has opened an investigation against Aspen into alleged anti-competitive conduct in relation to the supply of Fludrocortisone acetate 0.1 mg tablets and Dexamethasone 2 mg tablets in the UK. In 2016 the two products had a combined revenue of GBP11.1 million in the UK.



The investigation is at an early, information-gathering stage and the CMA has confirmed that, at this time, it has not reached any conclusion on whether competition law has been infringed. While Aspen is not currently in a position to comment on this investigation, it reaffirms its commitment to fair and open competition in the UK and around the world. Aspen takes compliance with competition laws very seriously and will work constructively with the CMA in its process.



Shareholders are advised that any material developments in these proceedings will be communicated through SENS. Shareholders should exercise care when reacting to information on this matter which has not been released by Aspen Holdings.
04-Oct-2017
(Official Notice)
Aspen welcomes the South African Competition Commission?s (?Commission?) decision to drop its investigation of Aspen for suspected abuse of dominance and excessive pricing on the basis that,

*an excessive pricing case cannot be sustained against Aspen; and

*the Commission?s investigation revealed that the revenues attributable to Myleran, Alkeran and Leukeran in South Africa are very low as they are at the end of their life cycle and these products are prescribed for very few patients.

14-Sep-2017
(C)
08-Sep-2017
(Official Notice)
Shareholders are advised that Aspen intends releasing its results for the year ended 30 June 2017 on Thursday, 14 September 2017 on SENS. This announcement will be followed by a presentation to members of the investment community on the same day in Johannesburg.



All interested stakeholders are invited to dial into the presentation scheduled for 08h30 (CAT) on 14 September 2017. Participation will be live, but on a listen-in basis only and those interested are requested to dial the numbers detailed below by no later than 08h15 (CAT) in order to register for the call.



Conference call dial-in details ? please dial one of the following numbers:

+27 11 535 3500

+27 10 201 6700



There will also be a live webcast which can be accessed using the following link: http://www.corpcam.com/Aspen14092017/



The slides accompanying the presentation will be available on the Aspen website (www.aspenpharma.com) in the Investor Information section shortly before the commencement of the presentation on 14 September 2017.



A playback of the webcast will be made available on the website approximately 2 hours after the presentation and will remain available until 30 October 2017.
30-Aug-2017
(Official Notice)
Aspen shareholders are hereby advised that normalised headline earnings per share (?NHEPS?), headline earnings per share and earnings per share for the year ended 30 June 2017 are expected to improve on those reported in the prior year, ended 30 June 2016, within the following ranges:

*NHEPS : 13% to 18% or 1428.0 to 1491.2

*Headline earnings per share: 43% to 48% or 1271.3 to 1315.7

*Earnings per share : 16% to 21% or 1096.7 to 1143.9



Notes:

1.NHEPS comprises headline earnings per share adjusted for specific non-trading items. NHEPS is the primary measure used by management to assess Aspen?s underlying financial performance.

2.The significant increase in headline earnings per share is attributable to the devaluation of Aspen?s Venezuelan business in the prior year.

3.The increase in earnings per share has been influenced by the following factors which negatively affected the prior year?s performance:

-the devaluation of Aspen?s Venezuelan business; and

-higher intangible asset impairments;

-offset by significant capital profits realised from the disposal of non-core businesses and products.



The financial results on which this trading announcement is based have not been reviewed or reported on by Aspen?s external auditors. Aspen?s results for the year months ended 30 June 2017 are scheduled to be published on SENS on 14 September 2017.

14-Jun-2017
(Official Notice)
Aspen Holdings has been informed that the Italian Court has dismissed Aspen?s appeal against the Italian Competition Authority (?ICA?) ruling relating to Aspen?s portfolio of oncology products distributed in Italy. The effect of this is that Aspen will be obliged to now pay the fine imposed by the ICA in the amount of ?5.2 million, plus interest thereon.



Aspen has noted the abridged principle judgment of the Italian Court announced earlier today and is awaiting the release of the full reasons for that judgment and the Italian Court?s assessment of the underlying facts, including that:

*prices for most of the relevant Aspen drugs in Italy had not been increased for between 40 and 60 years; and

*a generic version of one of the Aspen drugs in question has recently been approved in Italy with a list price of more than double that of the Aspen drug on an equivalent dose basis.



The reasons for the judgment will be handed down in due course. Aspen will engage its advisers and consider the matter further against receipt of those reasons, including Aspen?s automatic right to lodge a further appeal to the ?Council of State? appeal court.

14-Jun-2017
(Official Notice)
Shareholders are referred to the SENS announcement released by Aspen on 13 June 2017 wherein it was confirmed that:

- Aspen had noted the announcement made by the South African Competition Commission (?the Commission?) on 13 June 2017 that it will be investigating Aspen for suspected abuse of dominance in respect of the provision of cancer medication in South Africa;

- pharmaceutical prices in South Africa are approved by the South African Department of Health in terms of the Single Exit Price (?SEP?) regulatory framework which establishes a universal fixed price for each pharmaceutical product; and

- Aspen has not increased pricing of its products outside of this regulatory framework and has clearly demonstrated its commitment to providing quality medicines affordably over many years. The supply of the oncology products in question is no exception.



As further clarification, Aspen confirms that it has, to date, not had any engagement with the Commission on the matters contained in the Commission?s announcement of 13 June 2017 and welcomes the opportunity to meet and clarify the following key issues on the products listed by the Commission in its announcement:

- these products are all post-patent and have been for some time now;

- there are no obvious barriers precluding generic entry for these products. Invariably in situations like these, the lack of generic entry is either attributable to the sub-economical pricing of the branded products and/or an unattractive market size; and

- despite the lack of generic competition on these products, Aspen reiterates and emphasises that it has never increased the prices for these products in South Africa beyond the allowable SEP increases as gazetted by the South African Department of Health from time to time.



Aspen hopes to demonstrate, through its active engagement with the Commission and other affected stakeholders, its ongoing commitment to supplying the South African market with quality affordable medicines for which it is renowned. To provide context to shareholders it is confirmed that, while Aspen fully acknowledges the vital nature of the four oncology products listed in the Commission?s announcement, these products have a collective turnover of about R3 million in the South African private market.
13-Jun-2017
(Official Notice)
Aspen has noted the announcement by the South African Competition Commission that it will be investigating Aspen for suspected abuse of dominance in respect of the provision of cancer medication in South Africa. Aspen is committed to full and constructive engagement with the Competition Commission in this investigation.



It is reiterated that pharmaceutical prices in South Africa are approved by the Department of Health in terms of the Single Exit Price regulatory framework which establishes a universal fixed price for each pharmaceutical product. Aspen has not increased pricing of its products outside of this regulatory framework and has clearly demonstrated its commitment to providing quality medicines affordably over many years. The supply of the oncology products in question is no exception.



30-May-2017
(Official Notice)
Shareholders are referred to the Aspen Holdings SENS Announcement of 24 April 2017 wherein it was confirmed that the Democratic Alliance (?the DA?) had requested the South African Competition Commission to investigate the alleged anti-competitive conduct of Aspen in South Africa.



Aspen had further confirmed in this announcement that pharmaceutical prices are approved by the Department of Health in terms of the Single Exit Price regulatory framework which establishes a universal fixed price for each pharmaceutical product and that Aspen had not increased pricing of its products outside of this regulatory framework.



Aspen is pleased to note that the DA released a statement on 29 May 2017 wherein it confirms that: ?Following extensive high-level engagements between Aspen Pharmacare and the Health Portfolio of the Democratic Alliance, necessitated by a previous press release, the DA is satisfied that there is no evidence that Aspen is involved in the same practices that they are accused of having pursued in Europe.?
15-May-2017
(Official Notice)
Aspen confirms that the European Commission has opened proceedings to investigate certain actions of Aspen Holdings and certain of its European subsidiaries.



While Aspen is not currently in a position to comment on these proceedings, it reaffirms its commitment to fair and open competition in markets in the European Union and around the world. Aspen takes compliance with competition laws very seriously and will work constructively with the European Commission in its process.



Shareholders are advised that any material developments in these proceedings will be communicated through SENS. Shareholders should exercise care when reacting to information on this matter which has not been released by Aspen Holdings.





24-Apr-2017
(Official Notice)
Media reports that the Competition Commission has decided to take up the Democratic Alliance?s request to investigate the alleged anti-competitive conduct of Aspen in South Africa, in its preliminary investigation into the pharmaceutical sector, has reference.



Aspen welcomes the process and the opportunity to categorically set aside such allegations of anti- competitive behaviour. Aspen is committed to full and constructive engagement with the Competition Commission should it wish to pursue such an investigation.



It is worth noting that pharmaceutical prices are approved by the Department of Health in terms of the Single Exit Price regulatory framework which establishes a universal fixed price for each pharmaceutical product. Aspen has not increased pricing of its products outside of this regulatory framework.







18-Apr-2017
(Official Notice)
In reference to the articles reported in the European press on 14 and 15 April 2017, Aspen Holdings comments as follows:

*Aspen has clearly demonstrated its commitment to providing quality medicines affordably over many years. The supply of the oncology products in question is no exception.

*Aspen?s status as a responsible and committed provider of quality, affordable medicines is further validated by the role it has played in saving millions of lives across Africa through pioneering and supplying generic anti-retroviral medicine in Africa for the treatment of HIV/AIDS.

*The content of the reports concern matters that are sub-judice. Out of respect for the integrity of ongoing legal processes with European regulators, as well as the court in Italy, Aspen will not comment on these public allegations. Instead, Aspen looks forward to the opportunity to demonstrate the integrity and legality of its practices in the context of these legal processes.

*The oncology portfolio in question generated revenue in the European Union in Aspen?s financial year ended 30 June 2016 of EUR60 million (R963 million). The majority of the revenue was from the sale of tablets which have an average price of approximately EUR2 per tablet. The Aspen Group?s total revenue for the year ending 30 June 2016 was R35.6 billion.





09-Mar-2017
(C)
07-Mar-2017
(Official Notice)
Shareholders are advised that Aspen intends releasing its results for the half-year ended 31 December 2016 on Thursday, 9 March 2017 on SENS. This announcement will be followed by a presentation to members of the investment community on Friday, 10 March 2017 in Cape Town.



All interested stakeholders are invited to dial into the presentation scheduled for 08h30 (CAT) on 10 March 2017. Participation will be live but on a listen-in basis only and those interested are requested to dial the numbers detailed below by no later than 08h15 (CAT) in order to register for the call.



The slides accompanying the presentation will be available on the Aspen website (www.aspenpharma.com) in the Investor Information section shortly before the commencement of the presentation on 10 March 2017.



A playback of this presentation will be made available until 30 April 2017.

01-Mar-2017
(Official Notice)
Aspen shareholders are hereby advised that normalised headline earnings per share (?NHEPS?) , headline earnings per share and earnings per share for the 6 months ended 31 December 2016 are expected to vary from those reported in the comparative period, ended 31 December 2015, within the following ranges:

*NHEPS: 3% to 8% higher; 675.2 cents per share to 707.9 cents per share

*Headline earnings per share: 49% to 57% higher; 624.0 cents per share to 657.5 cents per share

*Earnings per share: 13% to 17% lower; 603.5 cents per share to 632.6 cents per share



Aspen`s interim results for the 6 months ended 31 December 2016 are scheduled to be published on SENS on 9 March 2017.
01-Mar-2017
(Official Notice)
Shareholders are referred to the announcement released by Aspen Holdings on 12 September 2016 wherein it was confirmed, inter alia, that Aspen Global Incorporated (?AGI?) had signed an agreement with GSK in terms whereof AGI would acquire a portfolio of anaesthetics globally (with the exception of certain territories, primarily North America) (?the Anaesthetics Transaction?). In consideration for the Anaesthetics Transaction AGI would pay an initial amount of GBP180 million and further milestone payments of up to GBP100 million, based on the results of the acquired portfolio in the 36 months following completion. Aspen Holdings announced that this transaction completed on 28 February 2017.
03-Jan-2017
(Official Notice)
Shareholders are referred to the announcement released by Aspen Holdings on 12 September 2016 wherein it was, inter alia, confirmed that:

*Aspen Global Incorporated (?AGI?) had exercised its option to acquire Fraxiparine and Arixtra in certain countries to which GSK retained the rights, most notably China, for a consideration of GBP45 million; and

*Pharmacare Ltd. (?Pharmacare?) and GSK had agreed to cancel the rights of Pharmacare to collaborate in the sub-Saharan business of GSK (?the SSA Collaboration?) and that GSK would pay Pharmacare GBP45 million as consideration for the cancellation of the SSA Collaboration.



Aspen Holdings announces that these transactions completed on 31 December 2016.



07-Dec-2016
(Official Notice)
Shareholders are advised that, at the Annual General Meeting (AGM?) of members held on Tuesday, 6 December 2016, a total of 325 961 981 or 71.41% of issued shares (456 435 185) were voted and that all resolutions were passed.
04-Nov-2016
(Official Notice)
Shareholders are advised that the company?s Integrated Report for the year ended 30 June 2016 has been finalised and that this report and the notice of the annual general meeting (?AGM?) to be held at its Durban offices on 6 December 2016 is being posted to shareholders. The Integrated Report, notice of AGM and the following documents are also available online at the company?s website www.aspenpharma.com:

- Unabridged Corporate Governance Statement and reports of the Aspen Audit - Risk and Social - Ethics committees for the 2016 financial year; and

- the Annual Financial Statements for the 2016 financial year (?AFS?).



The AFS contain no modifications to the reviewed provisional results which were published on SENS on 14 September 2016. The AFS were audited by PricewaterhouseCoopers Inc. Their unqualified report is available for inspection at the company?s registered office.



Notice is hereby given that the 18th annual general meeting of the shareholders of the company will be held at Aspen Place, 9 Rydall Vale Park, Douglas Saunders Drive, La Lucia Ridge Office Park, Durban, Kwa-Zulu Natal, on Tuesday, 6 December 2016 at 10:00.



Shareholders who, for whatever reason, experience postal delays and who do not receive the notice of the AGM in time to submit proxy forms to the company?s share transfer secretaries (Trifecta Capital) are requested to access the notice of AGM and other documents referred to above on the company?s website www.aspenpharma.com. A printable version of these documents in PDF format can also be emailed to shareholders upon request to the company Secretary ? rverster@aspenpharma.com or +27 31 580 8624.
29-Sep-2016
(Official Notice)
GlaxoSmithKline (?GSK?) has confirmed that, in accordance with its stated intention, it has successfully completed an accelerated bookbuild for the disposal of its remaining shareholding in Aspen (28.2 million ordinary shares or 6.2% of the Company?s issued share capital) conducted after the market closed on 28 September 2016.



The disposal in no way affects the ongoing collaboration between Aspen and GSK in South Africa and a number of other trading relationships between the two companies. David Redfern, GSK?s chief strategy officer, will remain a member of the Aspen board of directors.
14-Sep-2016
(C)
12-Sep-2016
(Official Notice)
Shareholders are advised that Aspen intends releasing its results for the year ended 30 June 2016 on Wednesday, 14 September 2016 on SENS. This announcement will be followed by a presentation to members of the investment community on Thursday, 15 September 2016 in Johannesbur
12-Sep-2016
(Official Notice)
07-Sep-2016
(Official Notice)
01-Sep-2016
(Official Notice)
Shareholders are referred to the announcement released by Aspen Holdings on 9 June 2016 wherein it was stated that:

*Aspen Global Incorporated (?AGI?) had signed an agreement with AstraZeneca AB and AstraZeneca UK (?AstraZeneca?) whereby AGI will acquire the exclusive rights to commercialise AstraZeneca?s global (excluding the USA) anaesthetics portfolio (?the Transaction?); and

*subject to the fulfilment of customary closing conditions, the Transaction was anticipated to complete during the first quarter of Aspen?s 2017 financial year.



Aspen is pleased to confirm that the necessary closing conditions to the Transaction have been met and that the Transaction, other than in respect of Ukraine and Zimbabwe which are subject to separate closing, will be effective from 1 September 2016.

16-Aug-2016
(Official Notice)
Shareholders are advised that, at the general meeting of members held on Monday,15 August 2016, a total of 278 345 192 or 60.99% of issued shares (456 403 819) were voted.

12-Aug-2016
(Official Notice)
Shareholders are advised that Ms Maureen Manyama has been appointed as a member of the Aspen Social - Ethics Committee with effect from 11 August 2016.



15-Jul-2016
(Official Notice)
Aspen is in the process of posting a notice to shareholders of a general meeting to be held at Building Number 1, Healthcare Park, Woodlands Drive, Woodmead, Johannesburg, Gauteng, on Monday, 15 August 2016 at 14:00.



This general meeting has been convened to:

Approve, as a special resolution, certain amendments to the Company?s Memorandum of Incorporation (?MOI?) relating to:

* fractional share entitlements ? the proposed changes are aimed at aligning the MOI with recent changes of the JSE Listings Requirements; and

* the timing of proxy form lodgments ? the proposed changes are aimed at aligning the MOI with recent case law on Section 58 of the Companies Act of 2008;



Re-elect, as an ordinary resolution, John Buchanan as a director who is retiring by rotation in terms of the memorandum of incorporation of the Company, who is eligible and offers himself for re-election. The board re-appointed Mr Buchanan as a director of the Company at its meeting held in September 2015 but this appointment was not confirmed by shareholders at the Company?s annual general meeting held on 7 December 2015 due to an oversight in the drafting of the notice to this meeting.



A copy of the notice of this general meeting is available from the Company Secretary, Riaan Verster (rverster@aspenpharma.com).
09-Jun-2016
(Official Notice)
08-Jun-2016
(Official Notice)
Aspen announced the successful closing of arrangements in respect of funding facilities equivalent to EUR3 000 000 000 (the ?Facilities?) for Aspen Holdings and its wholly owned subsidiaries Aspen Finance (Pty) Ltd., Pharmacare Ltd. t/a Aspen Pharmacare and Aspen Asia Pacific (Pty) Ltd. (together ?Aspen?) on 8 June 2016.



Bank of America Merrill Lynch International Ltd. (?BofAML?), Barclays Bank PLC and Absa Bank Ltd. (the ?EUR Coordinating Bookrunners - Arrangers?) acted as Joint Coordinators for the EUR facilities and The Standard Bank of South Africa Ltd. (?ZAR Coordinating Bookrunner - Arranger?) as Coordinator for the ZAR facilities. Bank of America Merrill Lynch International Ltd. acted as Documentation Agent and Facility Agent.

The Facilities were structured across EUR, ZAR and AUD term and revolving credit facilities with tenors of 2 to 5 years. All facilities were consolidated into a single facility agreement (?the Agreement?) with all creditors ranking pari-passu. The initial launch size of EUR1.5 billion for the EUR facilities was significantly oversubscribed (over 2x); allowing Aspen to upsize the EUR facilities to EUR2.25 billion and still offer the EUR banks considerable scale-back.



The deal was highly successful against the wider backdrop of significant market volatility and the challenging macroeconomic environment, and is a testament to Aspen?s strength as a corporation as well as its strong relationships with investors. Twenty-seven lenders committed to the transaction from across the USA, Europe, Africa, Australia and Asia, comprised of core banks as well as a number of new relationships.
17-May-2016
(Official Notice)
Shareholders are referred to the voluntary announcements released on the Stock Exchange News Service (?SENS?) on 1 December 2015 and 19 February 2016 wherein it was stated that:

* Aspen Global Incorporated (?AGI?), a wholly owned subsidiary of Aspen Holdings, had acquired the intellectual property and the approved Abbreviated New Drug Application in the United States in respect of the finished dose form of Hydroxyprogesterone Caproate (?HPC?) indicated for the treatment of certain female cancers and hormonal imbalances; and

* AGI was in advanced negotiations with a United States pharmaceutical company with proven capabilities in this category to distribute the HPC finished dose form in the United States.



Aspen takes pleasure in announcing that AGI has concluded an exclusive distribution and supply agreement with ANI Pharmaceuticals, Inc. (?ANI?) in terms whereof AGI will be responsible for supplying the HPC finished dose form, while ANI will be responsible for its marketing and distribution in the US.



Aspen currently manufactures the active pharmaceutical ingredient (?API?) for HPC and is a substantial supplier of HPC API to the United States. Aspen's launch of HPC injection is a realisation of Aspen?s stated intent to develop commercial opportunities in the United States which are aligned to the intellectual property available within the Group and the conclusion of this agreement signals a further milestone in the achievement of this stated intent.
31-Mar-2016
(Official Notice)
Appointment of an Independent Non-executive Director: Babalwa Ngonyama

The Aspen Board of Directors (?the Board?) confirms the appointment of Ms Babalwa Ngonyama as a director of Aspen Holdings and as a member of its Audit - Risk Committee with effect from 1 April 2016.



03-Mar-2016
(C)
01-Mar-2016
(Official Notice)
Shareholders are advised that Aspen intends releasing its results for the year ended 31 December 2015 on Thursday, 3 March 2016 on SENS. This announcement will be followed by a presentation to members of the investment community on Friday, 4 March 2016 in Cape Town.



All interested stakeholders are invited to dial into the presentation scheduled for 08h30 (CAT) on 4 March 2016. Participation will be live but on a listen-in basis only and those interested are requested to dial the numbers detailed below by no later than 08h15 (CAT) in order to register for the call.



Conference call dial-in details ? please dial one of the following numbers:

+27 11 353 3600

+27 10 201 6800



The slides accompanying the presentation will be available on the Aspen website (www.aspenpharma.com) in the Investor Information section shortly before the commencement of the presentation on 4 March 2016.



A playback of this presentation will be made available until 30 April 2016 ? this playback can be accessed by dialling one of the following numbers:

*South Africa - Other: +27 11 305 2030

*UK: 0 808 234 6771

*USA - Canada: 1 855 481 5363

*Australia: 1 800 091 250

*Replay code: 44316#







23-Feb-2016
(Official Notice)
19-Feb-2016
(Official Notice)
Shareholders are referred to the voluntary announcement released on the Stock Exchange News Service (?SENS?) on 1 December 2015 wherein it was stated that Aspen Global Incorporated (?AGI?), a wholly owned subsidiary of Aspen Holdings, had acquired the intellectual property and the approved Abbreviated New Drug Application in the United States in respect of the finished dose form of Hydroxyprogesterone Caproate (?HPC?).



Aspen is pleased to announce that AGI expects to launch the finished dose form product, indicated for the treatment of certain female cancers and hormonal imbalances, in the United States during its current financial year which ends on 30 June 2016. Aspen is in advanced negotiations with a United States pharmaceutical company with proven capabilities in this category to distribute the HPC finished dose form.



Aspen currently manufactures the active pharmaceutical ingredient (?API?) for HPC and is a substantial supplier of HPC API to the United States. Aspen's launch of HPC injection is a realisation of Aspen?s stated intent to develop commercial opportunities in the United States which are aligned to the intellectual property available within the group.



19-Jan-2016
(Official Notice)
Aspen shareholders are advised that Trifecta Capital Services (Pty) Ltd have been appointed as the Company?s Transfer Secretary with effect from 1 February 2016.



The new Transfer Secretary?s contact details, for existing and prospective shareholders, are:

Trifecta Capital Services (Pty) Ltd

Trifecta Capital House

31 Beacon Road

Florida-North

1709

South Africa



T: +27 (0) 860 22 22 13

E: aspen@trifectacapital.com



Postal Address:

PO Box 61272

Marshalltown

2107

South Africa



Please direct any enquiries you may have to the Company Secretary - Group Governance Officer (Riaan Verster) at rverster@aspenpharma.com

08-Dec-2015
(Official Notice)
Shareholders are advised that, at the Annual General Meeting (AGM?) of members held on Monday, 7 December 2015, a total of 321 877 844 or 70.53% of issued shares (456 351 337) were voted.
01-Dec-2015
(Official Notice)
Aspen announced that Aspen Global Incorporated (?AGI?), a wholly owned subsidiary of Aspen Holdings, has entered into an agreement with US-based McGuff Pharmaceuticals Inc. (?McGuff?), a wholly owned subsidiary of McGuff Company, Inc., to acquire the intellectual property and recently approved Abbreviated New Drug Application in the United States in respect of the finished dose form of Hydroxyprogesterone Caproate (?HPC?), a product indicated for the treatment of certain female cancers and hormonal imbalances. McGuff will also manufacture and supply the HPC injection product to AGI. It is expected that the product will be launched in the United States during 2016.



The transaction will provide a unique vertical integration opportunity as Aspen currently manufactures the active pharmaceutical ingredient (?API?) for HPC. The acquisition is in line with Aspen?s stated intent to develop commercial opportunities in the United States which are aligned to the intellectual property available within the Group.
03-Nov-2015
(Official Notice)
Shareholders are advised that the company?s Integrated Report for the year ended 30 June 2015 has been finalised and that this report and the notice of the annual general meeting (?AGM?) to be held at its Durban offices on 7 December 2015 will be posted to shareholders in due course. The Integrated Report, notice of AGM and the following documents are also available online at the company?s website www.aspenpharma.com:

* Corporate Governance Statement and reports of the Aspen Audit - Risk and Social - Ethics committees for the 2015 financial year (?Unabridged Corporate Governance Statement?);

* the Aspen Group?s Sustainability Report for the 2015 financial year (?Sustainability Report?); and

* the Annual Financial Statements the 2015 financial year (?AFS?).



The AFS contain no modifications to the reviewed provisional results which were published on SENS on 9 September 2015. The AFS were audited by PricewaterhouseCoopers Inc. Their unqualified report is available for inspection at the company?s registered office.



Notice is hereby given that the 17th annual general meeting of the shareholders of the company will be held at Aspen Place, 9 Rydall Vale Park, Douglas Saunders Drive, La Lucia Ridge Office Park, Durban, Kwa-Zulu Natal, on Monday, 7 December 2015 at 10:00.



Shareholders who, for whatever reason, experience postal delays and who do not receive the notice of the AGM in time to submit proxy forms to the company?s share transfer secretaries (Computershare) are requested to access the notice of AGM and other documents referred to above on the company?s website www.aspenpharma.com. A printable version of these documents in PDF format can also be emailed to shareholders upon request to the company Secretary ? rverster@aspenpharma.com or +27 31 580 8624.
09-Sep-2015
(C)
07-Sep-2015
(Official Notice)
Shareholders are advised that Aspen intends releasing its results for the year ended 30 June 2015 on 9 September 2015 on SENS. This announcement will be followed by presentations to members of the investment community on Thursday, 10 September 2015 and Friday, 11 September 2015, in Johannesburg and Cape Town respectively.



All interested stakeholders are invited to dial into the presentation scheduled for 08h30 (CAT) on 10 September 2015. Participation will be on a listen-in basis only and those interested are requested to dial the numbers detailed below by no later than 08h15 (CAT) in order to register for the call.



Conference call dial-in details:

* South Africa: 0 800 200 648



The slides accompanying the presentation will be available on the Aspen website (www.aspenpharma.com) in the Investor Information section shortly before the commencement of the presentation on 10 September 2015. A playback of this presentation will also be made available after the presentation for a limited time. Playback details will be published on the Aspen website.
28-Aug-2015
(Official Notice)
Aspen shareholders are hereby advised that normalised headline earnings per share (?NHEPS?), headline earnings per share and earnings per share for the 12 months ended 30 June 2015 are expected to exceed those reported in the comparative period, ended 30 June 2014, within the following ranges:

* NHEPS : 1191.9 to 1245.1

* Headline earnings per share: 1118.0 to 1168.9

* Earnings per share : 1108.9 to 1163.8



Aspen`s results for the 12 months ended 30 June 2015 are scheduled to be published on SENS on 9 September 2015.
12-Aug-2015
(Official Notice)
Shareholders are advised that Dr Judy Dlamini has indicated her intention to resign as both chairman and director of the company at Aspen?s AGM, scheduled for 7 December 2015. The Aspen board has agreed that Mr Kuseni Dlamini, currently an independent non-executive director of the company, be appointed as chairman with effect from that date.
11-Aug-2015
(Official Notice)
Shareholders are referred to the announcement released by Aspen Holdings on 21 May 2015 wherein it was confirmed, inter alia, that certain of its wholly owned Australian subsidiaries (collectively ?Aspen Australia?), had entered into an agreement with Strides (Australia) Pharma (Pty) Ltd. (?Strides Australia?), a company incorporated in Australia, in terms whereof Aspen Australia would divest to Strides Australia, a portfolio of approximately 130 products.



It was also announced that Aspen Global Incorporated (?AGI?), a wholly owned subsidiary of Aspen Holdings incorporated in Mauritius, had entered into a separate transaction to divest of a portfolio of six branded prescription products to Strides Pharma Global Pte Ltd. (?Strides Singapore?), a company incorporated in Singapore.



Aspen confirmed that all the contractual conditions precedent in respect of both these transactions were satisfied on 1 August 2015 and that these transactions are expected to complete on 31 August 2015.
05-Aug-2015
(Official Notice)
Renewal of Cautionary Announcement- Possible Infant Nutritionals Business Acquisition

Shareholders are referred to the cautionary announcement released by Aspen on 14 May 2015 in which shareholders were advised that Aspen was engaged in discussions regarding the possible acquisition of an infant nutritionals business and the renewal of that cautionary announcement released on 25 June 2015.



Shareholders are advised that these discussions remain ongoing and may have a material effect on the price of Aspen?s securities if successfully concluded and accordingly shareholders are advised to continue exercising caution when dealing in Aspen?s securities.

30-Jun-2015
(Official Notice)
In May 2005, the shareholders of Aspen approved a scheme of arrangement to facilitate the acquisition of ordinary shares in Aspen (?Aspen Shares?) by Imithi Investments (Pty) Ltd. (?Imithi?), the shareholders of which comprise a grouping of broad-based BEE entities (the ?BEE Transaction?). The BEE Transaction was designed with the objective of ensuring that a meaningful portion of Aspen?s equity is owned by black people and that black people have a meaningful role in Aspen`s operations, management and development.



Pursuant to the BEE Transaction, Imithi acquired 13 400 000 new Aspen Shares, representing 3.1% of the Aspen Shares currently in issue, and 17 600 000 new variable rate, voting, convertible, redeemable, cumulative A preference shares (the ?Aspen Preference Shares?). In order to facilitate the redemption of its funding obligations, Imithi disposed of 9 839 276 Aspen Shares in June 2012, as allowed for in terms of the agreements governing the BEE Transaction. In addition, and in terms of these agreements, 17 600 000 new variable rate, voting, convertible, redeemable, cumulative A preference shares held by Imithi were converted into 17 600 000 ordinary shares in June 2012, bringing Imithi?s total shareholding in Aspen to 21 160 724 Aspen Shares.



Termination of Lock-up Period

In terms of the agreements governing the BEE Transaction the various shareholders of Imithi were contractually committed to remain shareholders of Imithi until 21 June 2015 (?Lock-up Period?). As this Lock-up Period has now expired and certain Imithi shareholders wish to hold their proportionate share (after costs) of Aspen Shares directly, Imithi made a proportionate ?in specie? distribution to them of the Aspen Shares on 29 June 2015. In order to facilitate the payment of the costs (including taxation) related to this distribution, approximately 3.6 million Aspen Shares were disposed of by Imithi.
25-Jun-2015
(Official Notice)
Renewal of Cautionary Announcement- Possible Infant Nutritionals Business Acquisition



Shareholders are referred to the cautionary announcement released by Aspen on 14 May 2015 in which shareholders were advised that Aspen was engaged in discussions regarding the possible acquisition of an infant nutritionals business.



Shareholders are advised that these discussions remain ongoing and may have a material effect on the price of Aspen?s securities if successfully concluded and accordingly shareholders are advised to continue exercising caution when dealing in Aspen?s securities.
21-May-2015
(Official Notice)
Aspen announced that certain of its wholly owned Australian subsidiaries (collectively "Aspen Australia"), have entered into an agreement with Strides (Australia) Pharma (Pty) Ltd. ("Strides Australia"), a company incorporated in Australia, in terms whereof Aspen Australia will divest to Strides Australia, a portfolio of approximately 130 products for a consideration of approximately AD265 million ("the Australian Transaction").



The portfolio of products in the Australian Transaction comprises a generic pharmaceutical business together with certain branded pharmaceutical assets. This portfolio recorded revenue of AUD106 million and a direct contribution to profit before tax of AUD26 million for the year ended 30 June 2014.



In a separate transaction, Aspen Global Incorporated ("AGI"), a company incorporated in Mauritius, has entered into an agreement with Strides Pharma Global Pte Ltd. ("Strides Singapore"), a company incorporated in Singapore, in terms whereof AGI will divest to Strides Singapore, a portfolio of six branded prescription products, for a consideration of approximately USD92 million. This portfolio recorded revenue of USD12 million and a direct contribution to profit before tax of USD10 million for the year ended 30 June 2014.



Strides Australia and Strides Singapore are wholly owned subsidiaries of Strides Arcolab Ltd. ("Strides"), a pharmaceutical company headquartered and publicly listed in India. Strides have a key focus on the development and manufacture of IP-led, niche pharmaceuticals products.



These transactions form part of Aspen's communicated strategic intent to focus attention in areas where most value can be added and to lessen complexity.



The transactions are conditional upon, inter alia, the approval of the Australian Foreign Investments Review Board.
14-May-2015
(Official Notice)
Shareholders are advised that Aspen is currently engaged in discussions regarding a possible acquisition of an infant nutritionals business. These discussions may have a material effect on the price of Aspen's securities if successfully concluded and accordingly shareholders are advised to exercise caution when dealing in the Company?s securities.
11-May-2015
(Official Notice)
Aspen announced that Pharmacare Ltd. (?Pharmacare?), a wholly owned subsidiary of Aspen Holdings and the Group?s primary South African trading company, has concluded a set of agreements with Litha Pharma (Pty) Ltd. ("Litha") (a wholly owned South African subsidiary of Endo International Plc) in terms which Pharmacare will divest a business unit which forms part of its pharmaceutical division to Litha for a consideration of approximately R1.6 billion (?the Transaction?).



The business unit concerned has a product portfolio comprising injectables and established brands. This portfolio recorded revenue of R362 million and a direct contribution to profit before tax of R136 million for the year ended 30 June 2014.



The Transaction forms part of Aspen?s communicated strategic intent to focus attention in areas where most value can be added and to lessen complexity.



The Transaction is conditional upon, inter alia, the approval of the South African Competition Authorities.
20-Mar-2015
(Official Notice)
Shareholders are referred to the SENS announcement released by the Company on 13 March 2015 wherein it was confirmed that GlaxoSmithKline (?GSK?) had announced the completion of the disposal of half of its 12.4% shareholding in Aspen (equivalent to 28.2 million ordinary shares).



In accordance with section 122(3)(b) of the Companies Act, No. 71 of 2008 (?the Act?) and section 3.83(b) of the JSE Listings Requirements, holders of ordinary shares in the Company are advised that GSK has now formally provided Aspen with the required notice in terms of section 122(1)(a) of the Act. This notice confirms that GSK has disposed of 28.2 million ordinary Aspen shares and that, as a result, its remaining beneficial interest in Aspen now amounts to 6.2% of the total number of shares in issue.



Aspen will file the required notice with the Takeover Regulation Panel as required in terms of section 122(3)(a) of the Act.
20-Mar-2015
(Official Notice)
The Aspen board of directors (?the board?) confirms the resignation from the board of Mr Mogammed Rafique Bagus with effect from 31 March 2015.



Mr Bagus has, after 12 years of dedicated service to the Aspen Group as an independent non- executive director, confirmed that other commitments will keep him engaged for at least a year, whereafter he may again be available to serve as director.
13-Mar-2015
(Official Notice)
GlaxoSmithKline (?GSK?) has announced the completion of the disposal of half of its 12.4% shareholding in Aspen (equivalent to 28.2 million ordinary shares). These shares were sold by means of an accelerated book build offering process which resulted in the shares being sold at ZAR 372 per share, raising gross proceeds of approximately ZAR 10.5 billion.



Following settlement of the sale, GSK will hold 28.2 million ordinary shares in Aspen, representing approximately 6.2% of the issued share capital. The Board of Aspen has agreed that Mr David Redfern, recently appointed as GSK?s nominee director to replace Mr Abbas Hussain on the Board, will remain a director of Aspen.
05-Mar-2015
(C)
26-Feb-2015
(Official Notice)
Aspen shareholders are hereby advised that normalised headline earnings per share (?NHEPS?) from continuing operations, headline earnings per share and earnings per share for the 6 months ended 31 December 2014 are expected to exceed those reported in the comparative period, ended 31 December 2013, within the following ranges:



Cents per share - Comparative period

NHEPS from continuing operations: 557.0 to 580.4 - 468.0

Headline earnings per share: 530.2 to 551.5 - 424.2

Earnings per share: 525.0 to 546.2 - 423.4



The favourable results reflected above are despite the effect of material foreign exchange losses arising mainly as a consequence of the strengthening of the US Dollar against Aspen?s primary trading currencies.



The financial results on which this trading announcement is based have not been reviewed or reported on by Aspen`s external auditors.



Aspen`s interim results for the 6 months ended 31 December 2014 are scheduled to be published on SENS on 5 March 2015.
23-Feb-2015
(Official Notice)
Shareholders are advised that Aspen intends releasing its results for the six month period ended 31 December 2014 on 5 March 2015 on SENS. A presentation on the interim results will take place on Friday, 6 March 2015 in Cape Town at the Investec Specialist Bank Healthcare Conference. All interested stakeholders are invited to dial into the presentation scheduled for 08h30 (CAT) on 6 March 2015. Participation will be on a listen-in basis only and those interested are requested to dial the numbers detailed below by no later than 08h15 (CAT) in order to register for the call.
23-Jan-2015
(Official Notice)
Aspen is pleased to announce that Aspen Global Incorporated (?AGI?), a wholly owned subsidiary of Aspen, has entered into an agreement with Novartis AG in terms of which it will acquire the rights to Mono-Embolex?, an injectable anti-coagulant, for a consideration of USD142.3 million.



Mono-Embolex is a heparin based anti-coagulant sold in the same therapeutic category as Aspen?s Arixtra and Fraxiparine. This product is, however, the only low molecular weight heparin that offers patients weight-independent dosing, thereby combining ease of administration with the proven efficacy in prophylaxis and therapy of deep vein thrombosis.



The product presents an excellent strategic fit with the Group?s recent acquisitions in this therapeutic area and will be positioned as a simple-to-use once daily prophylaxis treatment supporting Aspen?s other current anti-coagulant offerings. As the product is only commercialised in Germany, Switzerland and Austria it presents Aspen with an opportunity to launch it in other countries. The product recorded revenue of EUR68 million in 2013.



The transaction is subject to the approval of the German competition authorities.
24-Dec-2014
(Official Notice)
2014 Anti-Retroviral Tender Results



Following the announcement of the Anti-Retroviral (ARV) Tender results by the South African National Treasury Department, Aspen is pleased to announce that its South African operating company (Pharmacare Ltd. t/a Aspen Pharmacare) has been successful in winning a number of key products in the tender Aspen?s award included 25% of the Fixed Dose Combination (FDC) containing Tenofovir, Emtracitibine and Efavirenz, which will be used to treat upwards of 80% of 1st line adult treatment , in spite of strong competition. The tender is effective for a period of three years, commencing 1 April 2015.



Aspen secured R2.7 billion or approximately 20% of the awarded tender value based upon expected future demand as published in the invitation to tender. The tender value is estimated to be approximately R14 billion over 3 years. The South African ARV Tender is the largest of its kind in the world. Aspen has been a leading supplier to this tender since inception of the programme, providing a consistent and reliable supply of high-quality ARV products to the State.



Aspen was awarded a share of the following products:

Abacavir Solution 20mg/ml: 45%

Atazanavir 150mg: 36%

Duranavir 600mg: 100%

Etravarine 100mg: 100%

Lamivudine 150mg (of tendered quantity): 100%

Nevirapine: 40%

Stavudine 15mg: 100%

Stavudine 20mg: 100%

Stavudine 30mg: 100%

Tenofovir (of tendered quantity): 25%

Tenofovir, Emtracitibine, Efavirenz: 25%



These tender results again confirm Aspen`s reputation for cost competitiveness against both local and foreign suppliers. Aspen`s range of ARV`s are produced at its world-class manufacturing facilities in Port Elizabeth, South Africa. This has resulted in unlocking capacity to accommodate growing demand from Aspen`s domestic and foreign territories and also contributed towards further optimising manufacturing efficiencies.

10-Dec-2014
(Official Notice)
Shareholders are advised that, at the Annual General Meeting (AGM?) of members held on Monday, 8 December 2014, all ordinary and special resolutions as proposed in the Notice of Annual General Meeting were approved by the requisite majority of members. A total of 350 289 729 or 76.76% of issued shares (456 348 537) were voted at this AGM (including abstentions).
10-Dec-2014
(Official Notice)
Shareholders are advised that Abbas Hussain has confirmed that he intends to tender his resignation as a director of the Company with effect from 1 February 2015 due to a change in his responsibilities at GlaxoSmithKline ("GSK"). David Redfern has been nominated by GSK to replace Abbas as its nominee director on the Aspen Board with effect from that date. David is GSK's Chief Strategy Officer and the Chairman of ViiV Healthcare Ltd. His extensive expertise in the international pharmaceutical industry is expected to add value to Aspen.



The Board wishes to express its sincere appreciation to Abbas for his valuable contribution to Aspen over the past 5 years and wish him every success in his future endeavours.

11-Nov-2014
(Official Notice)
Shareholders are referred to the no change statement and notice of annual general meeting ("AGM") announcement released by the company on 30 October 2014. Please be advised that the form of proxy attached to the issued notice of AGM erroneously confirms that the date on which proxy forms must be returned to the company's transfer secretaries as being 28 November 2014, while the correct return date for proxy forms is Friday, 5 December 2014 (as accurately reflected on the notice of AGM).



A revised form of proxy has been posted on the company's website (www.aspenpharma.com) or can be obtained from the Company Secretary (rverster@aspenpharma.com) should this be required. Both versions of the form of proxy received before 09:00 on Friday, 5 December 2014 will be accepted and effective at the AGM to be held on Monday, 8 December 2014 at 10:00.
31-Oct-2014
(Official Notice)
Aspen announced that it has concluded a transaction to acquire a 50% shareholding in New Zealand New Milk Ltd. ("NZNM"), a producer of infant milk formula in Auckland, New Zealand. In terms of a supply agreement concluded between Aspen Global Incorporated and NZNM, long-term supply of infant milk formula for distribution by Aspen in Australia will be secured. NZNM is one of a limited number of companies which holds the required endorsements from the Chinese regulatory authorities to produce infant milk formula for this key territory and the investment in NZNM represents another step towards Aspen?s aspirations to enter the Chinese infant milk formula sector, valued at approximately USD15 billion.
30-Oct-2014
(Official Notice)
Shareholders are advised that the company's Integrated Report for the year ended 30 June 2014 has been finalised and that this report and the notice of the annual general meeting ("AGM") to be held on 8 December 2014 will be posted to shareholders in due course. The Integrated Report, notice of AGM and the following documents are also available online at the company's website www.aspenpharma.com:

* Corporate Governance Statement and reports of the Aspen Audit - Risk and Social - Ethics committees for the 2014 financial year ("Unabridged Corporate Governance Statement");

* the Aspen Group's Sustainability Report for the 2014 financial year ("Sustainability Report"); and

* the Annual Financial Statements the 2014 financial year ("AFS").



The AFS contain no modifications to the reviewed provisional results which were published on SENS on 10 September 2014. The AFS were audited by PricewaterhouseCoopers Inc. Their unqualified report is available for inspection at the company's registered office.



Notice is hereby given that the 16th annual general meeting of the shareholders of the company will be held at Building Number 1, Healthcare Park, Woodlands Drive, Woodmead, Johannesburg, Gauteng, on Monday, 8 December 2014 at 10:00.



Shareholders are advised that, due to the current ongoing labour disruption at the South African Post Office, they may experience postal delays and may not receive the notice of the AGM in time to submit proxy forms to the company's share transfer secretaries (Computershare). Shareholders experiencing difficulty in this regard are requested to access the notice of AGM and other documents referred to above on the company's website www.aspenpharma.com. A printable version of these documents in PDF format can also be emailed to shareholders upon request to the company Secretary - rverster@aspenpharma.com or +27 31 580 8624.
20-Oct-2014
(Official Notice)
09-Oct-2014
(Official Notice)
Aspen announced that Aspen Global Incorporated ("AGI"), a wholly owned subsidiary of Aspen Holdings Incorporated (the Group), has entered into an agreement with GlaxoSmithKline ("GSK") whereby GSK will take an equity stake in Aspen's newly established subsidiary in Japan named Aspen Japan K.K. ("Aspen Japan"). In terms of this agreement Aspen will hold a 75% equity share in Aspen Japan, while GSK will hold a 25% share. It is intended that Aspen Japan will, where feasible, be the conduit through which the Group will conduct its commercial operations in Japan in a strategic alliance with GSK. The collaboration will be operated in accordance with the following salient terms:

* AGI will transfer the marketing authorisations and grant perpetual distribution rights to Aspen Japan for all products currently being marketed and distributed on behalf of Aspen in Japan;

* GSK will transfer the marketing authorisations and grant distribution rights to Aspen Japan for certain mature products in GSK's portfolio;

* GSK will provide Aspen Japan with a pipeline of authorised generics for a number of GSK's products;

* AGI will offer Aspen Japan the rights to all future products that it acquires or licenses in Japan; and

* AGI will be responsible for the management of Aspen Japan and for the commercialisation of all the products in Aspen Japan's portfolio.



Completion of this agreement will be subject to a number of conditions precedent, one of which is Aspen Japan obtaining accreditation as a Marketing Authorisation Holder from the relevant Japanese regulatory authority. It is expected that, through this agreement with GSK, Aspen will be able to harness more opportunities and grow its presence in one of the world's biggest pharmaceutical markets.
26-Sep-2014
(Official Notice)
Shareholders are referred to the announcement in respect of Aspen?s provisional financial results for the year ended 30 June 2014, as released by Aspen Holdings on 10 September 2014 and wherein it was confirmed, inter alia, that Aspen Global Incorporated (AGI) had entered into an agreement with Mylan Ireland Ltd (Mylan) in terms of which AGI will dispose of its rights to commercialise the fondaparinux products it recently acquired from GSK (being Arixtra and the authorised generic thereof) in the United States (US) to Mylan (the Transaction). In terms of this Transaction, AGI will enter into a supply agreement to supply these fondaparinux products to Mylan on specified terms. The announcement further confirmed that the Transaction would complete upon the satisfaction of certain conditions precedent, including regulatory approvals. Aspen is pleased to confirm that all conditions precedent have been met and that the Transaction was completed on 25 September 2014.

10-Sep-2014
(C)
08-Sep-2014
(Official Notice)
Shareholders are advised that Aspen intends releasing its results for its 2014 financial year on 10 September 2014 on SENS. This announcement will be followed by presentations to members of the investment community on Thursday, 11 September 2014 and Friday, 12 September 2014, in Johannesburg and Cape Town respectively. All interested stakeholders are invited to dial into the Johannesburg presentation scheduled for 08h30 (CAT) on 11 September 2014. Participation will be on a listen-in basis only and those interested are requested to dial the numbers detailed below by no later than 08h15 (CAT) in order to register for the call.

03-Sep-2014
(Official Notice)
The company refers to the disclosures made by Aspen's executive directors during a pre-closed period conference call with members of the investment community on 27 June 2014 ("the Conference Call") and the subsequent SENS announcement dated 30 June 2014.



Based on the representations made by the company to the JSE, as well as the relevant facts gathered by the JSE in respect of this matter, the JSE has informed the company that it did not find any breach of the JSE's Listings Requirements as the contents of the Conference Call were already in the public domain and/or were not materiality price sensitive if understood in its context. The investigation was thus closed by the JSE.
29-Aug-2014
(Official Notice)
Aspen shareholders are hereby advised that normalised diluted headline earnings per share ("NDHEPS"), earnings per share and headline earnings per share for the 12 months ended 30 June 2014 are expected to exceed those reported in the comparative period, ended 30 June 2013, within the following ranges:



NDHEPS comprises diluted headline earnings per share adjusted for specific non- trading items. NDHEPS is the primary measure used by Aspen to assess its underlying financial performance.

The growth in earnings per share has benefited from capital profits on the sale of certain non-core products during the year and foreign exchange gains related to transaction funding, partly offset by the effect of significant transaction costs relating to new business acquisitions.

The growth in headline earnings per share is less than the growth in earnings per share primarily due to the exclusion of the capital profits from the sale of certain non- core products in the calculation of headline earnings.



The financial results on which this trading announcement is based have not been reviewed or reported on by Aspen's external auditors.



Aspen's provisional results for the 12 months ended 30 June 2014 are scheduled to be published on SENS on 10 September 2014.
30-Jun-2014
(Official Notice)
Shareholders are referred to the announcement of 19 May 2014 wherein it was confirmed that Ms Maureen Manyama-Matome had been appointed to the Aspen Board of Directors ("the Board") as an independent non-executive director with effect from 1 June 2014. The Board announced that Ms Maureen Manyama-Matome has been appointed as a member of the Aspen Audit - Risk Committee with effect from 26 June 2014.
30-Jun-2014
(Official Notice)
19-May-2014
(Official Notice)
The Aspen Board of Directors announced that Ms Maureen Manyama-Matome has been appointed to the Board as an independent non-executive director with effect from 1 June 2014.
06-Mar-2014
(C)
21-Feb-2014
(Official Notice)
Aspen shareholders are hereby advised that diluted normalised headline earnings per share ("DNHEPS") from continuing operations, headline earnings per share and earnings per share for the 6 months ended 31 December 2013 are expected to exceed those reported in the comparative period, ended 31 December 2012, within the following ranges:



DNHEPS from continuing operations -- 20% to 24%

Headline earnings per share -- 12% to 16%

Earnings per share -- 12% to 16%



Aspen's interim results for the 6 months ended 31 December 2013 are scheduled to be published on SENS on 6 March 2014.
31-Dec-2013
(Official Notice)
Shareholders are referred to the announcements released by Aspen Holdings on 27 June, 1 October and 31 October 2013 wherein it was confirmed, inter alia, that Aspen had reached an agreement on an option granted to Aspen Global Incorporated (AGI) to acquire a portfolio of 11 branded finished dose form molecules (the Products) from MSD, covering a diverse range of therapeutic areas and including products that use APIs manufactured by the API Business recently acquired from MSD.



It was also confirmed that AGI had, subsequently, exercised the option to acquire the Products on 31 October 2013 and that, subject to the fulfilment of certain conditions precedent, the effective date of the Product transaction resulting from the exercise of the option would be 31 December 2013. Aspen is pleased to confirm that all the contractual conditions precedent in respect of the Product acquisition have been met and that the acquisition of the Products will complete today, 31 December 2013.
31-Dec-2013
(Official Notice)
Shareholders are referred to the terms announcement and circular released by Aspen Holdings, on 30 September and 9 October 2013 respectively, wherein it was confirmed that the Aspen Group (Aspen) had entered into an agreement with GSK in terms whereof Aspen would acquire:

*the Business - the business carried on by GSK in respect of the commercialisation of Arixtra, Fraxiparine and Fraxodi trademarks, as marketed by GSK or its distributors in the world (the Relevant Markets) except for the People's Republic of China (including its Special Administrative Regions, Hong Kong and Macau), India and Pakistan (collectively, the Excluded Territories) with effect from 1 January 2014, subject to certain conditions precedent being met; and

*the Manufacturing Business- the business carried out at the Notre Dame de Bondeville manufacturing site (the Site) relating to the manufacture of the Products for commercialisation in the Relevant Markets and Excluded Territories and the manufacture of diluents for GSK, during the second quarter of 2014, subject to certain conditions precedent being met.



Shareholders are advised that all conditions precedent have been met in respect of the acquisition of the Business and the Manufacturing Business. As a result the acquisition of the Business has completed with effect from today and all of the material commercial operations related to the Business will therefore transfer to Aspen on 1 January 2014. The acquisition of the Manufacturing Business is expected to complete during the second quarter of 2014.
20-Dec-2013
(Official Notice)
Shareholders of Aspen are referred to the announcement to shareholders dated 18 April 2013 wherein it was announced that Aspen Group companies ("Aspen") had concluded agreements with Nestl? S.A. in respect of the acquisition of certain rights to intellectual property licenses, net assets and shares in the IN businesses conducted by Pfizer which distribute a portfolio of IN products in Australia (the "Australian IN business") and certain Southern African territories (South Africa, Botswana, Namibia, Lesotho, Swaziland and Zambia)(the "Southern African IN business") for a total purchase consideration of USD 215 million. As announced on 18 April 2013, the Australian competition authorities had approved Aspen's acquisition of the Australian IN business and the transaction became effective in Australia from 28 April 2013. Approval of the South African competition authorities was pending at the date of that announcement.



Aspen announced that the South African Competition Tribunal has, in a ruling made on 19 December 2013, confirmed its approval of Aspen's acquisition of the Southern African IN business. This was the only outstanding condition precedent in respect of the finalisation of the acquisition of this business and the transaction is expected to be completed on 27 January 2014.
04-Dec-2013
(Official Notice)
Shareholders were advised that, at the annual general meeting of Aspen shareholders held on Tuesday, 3 December 2013, the ordinary and special resolutions proposed in terms of the notice of annual general meeting dated 21 October 2013 were all passed by the requisite majorities.
11-Nov-2013
(Official Notice)
Shareholders are referred to the announcement released by Aspen on 30 June 2013 wherein it was confirmed that it would be proposed to shareholders of Aspen that Aspen Global Incorporated ("AGI"), a wholly owned subsidiary of Aspen, acquire from GlaxoSmithKline plc ("GSK") the Arixtra and Fraxiparine/Fraxodi brands ("the Brands") and business worldwide, except in China, Pakistan and India ("the Excluded Territories") and Aspen Holdings acquire from GSK a specialised sterile production site which manufactures the Brands at Notre Dame de Bondeville, France ("the Site"), collectively ("the Proposed Transaction"). It was also confirmed that the aggregate purchase consideration payable by Aspen Holdings and AGI in respect of the Proposed Transaction was GBP600 million.



As the Proposed Transaction was categorised as a Category 2 transaction in terms of the Listings Requirements of the JSE, with GSK being a material shareholder and a related party to Aspen Holdings, shareholders were requested to approve the Proposed Transaction by means of an ordinary resolution (i.e. with 50% of the votes cast in favour of the Proposed Transaction), excluding shares held by GSK and its associates, at a general meeting of shareholders called for this purpose on 8 November 2013. Aspen has pleasure in confirming that the ordinary resolution put to shareholders to approve the Proposed Transaction at this general meeting was carried with 100% of votes having been cast in favour of it.
04-Nov-2013
(Official Notice)
Shareholders were advised that the company's Integrated Report for the year ended 30 June 2013 and notice of the annual general meeting were posted to shareholders on Monday, 4 November 2013.



The annual financial statements of the company, which are available electronically at www.aspenpharma.com or from the company secretary (rverster@aspenpharma.com), contain no modifications to the reviewed results as published on 11 September 2013.



Notice was also given that the 15th annual general meeting of the shareholders of the company will be held at Building Number 1, Healthcare Park, Woodlands Drive, Woodmead, Johannesburg, Gauteng, on Tuesday, 3 December 2013 at 10:00.
31-Oct-2013
(Official Notice)
Shareholders are referred to the announcement released by Aspen Holdings on 27 June 2013 wherein it was confirmed that Aspen Global Incorporated had, amongst other things, reached an agreement on an option (the Option) to acquire a portfolio of eleven branded finished dose form molecules (the Products) from MSD, covering a diverse range of therapeutic areas. Aspen Holdings is pleased to announce that Aspen Global Incorporated has exercised the Option. Subject to the fulfilment of certain conditions precedent the effective date of the Product transaction resulting from the exercise of the Option will be 31 December 2013.

28-Oct-2013
(Official Notice)
Further to the announcement released on 7 August 2013 wherein shareholders of Aspen Holdings were advised that a number of the Aspen Group's companies had concluded agreements with Nestl? SA in respect of the acquisition of certain license rights to intellectual property, net assets (including an IN production facility located in Vallejo, Mexico) and shares in the IN businesses, previously owned by Pfizer and presently conducted by Nestl? and Pfizer in Latin America, predominantly Mexico, Venezuela, Colombia, Ecuador, Chile, Peru, Central America and the Caribbean (collectively, "the Transaction"), shareholders are advised that Aspen has met all of its contractual and regulatory conditions precedent and that the transaction was successfully closed on 28 October 2013.
24-Oct-2013
(Official Notice)
With reference to the announcement to Aspen's shareholders made on 13 September 2013, Aspen is pleased to confirm that Bank of America Merrill Lynch and The Standard Bank of South Africa Ltd. (together the "Initial Mandated Lead Arrangers and Bookrunners") have successfully closed the syndication of the USD1 985 000 000 acquisition finance facilities for Aspen Global Incorporated ("AGI") a 100% owned subsidiary of Aspen and that this syndication was fully subscribed. Shareholders are also advised that the initial syndication amount of USD2 035 000 000 has been reduced to USD1 985 000 000 due to reduced funding requirements.



The facilities which were partially underwritten by the Initial Mandated Lead Arrangers will be used to (i) support current and prospective acquisitions being undertaken by AGI; and (ii) refinance all of AGI's existing term bank debt.



The Facilities

The summary terms of the AGI facilities are detailed in the relevant SENS note.



With respect to the syndication of the ZAR7 330 000 000 facilities for Pharmacare (a 100% owned subsidiary of Aspen) and Aspen, it is confirmed that commitments have been received, and that the syndication has been successfully closed, with significant support from the local ZAR banking and institutional market.
10-Oct-2013
(Official Notice)
Shareholders are referred to the announcement released by Aspen on 30 September 2013 in respect of a proposed transaction in terms whereof Aspen Global Incorporated, a wholly owned subsidiary of Aspen, will acquire from GSK the Arixtra and Fraxiparine/Fraxodi brands and business worldwide, except in China, Pakistan and India and Aspen will acquire from GSK a specialised sterile production site which manufactures the Brands at Notre Dame de Bondeville, France, collectively ("the Proposed Transaction").



Shareholders are advised that the circular relating to the Proposed Transaction was posted to Aspen shareholders, today, 10 October 2013 and that the general meeting of shareholders to approve the transaction will be held at Aspen Park, Building 1, 98 Armstrong Drive, La Lucia Ridge, Durban at 15:00 on Friday, 8 November 2013. A copy of the circular is available on the Company's website http://www.aspenpharma.com/.
01-Oct-2013
(Official Notice)
Shareholders are referred to the announcement released by Aspen Holdings on 27 June 2013 wherein it was confirmed that the Aspen Group ("Aspen") had:

*reached an agreement on an option to acquire a portfolio of 11 branded finished dose form molecules ("the Products") from MSD, covering a diverse range of therapeutic areas and including products that use APIs manufactured by the API Business.



As confirmed in the announcement released on 27 June 2013, the expected effective date of the Products acquisition, through the exercise of the option, is 31 December 2013 and a further announcement will be made once this aspect of the Transactions has been completed.
01-Oct-2013
(Official Notice)
Shareholders are referred to the announcement released by Aspen Holdings on 27 June 2013 wherein it was confirmed that the Aspen Group ("Aspen") had:

*signed an agreement with MSD (known as Merck in the United States and Canada) for the acquisition of an active pharmaceutical ingredient ("API") manufacturing business which manufactures for MSD and the market generally and which is located in the Netherlands with a satellite facility and sales office in the US ("the API Business"); and



Aspen Holdings is pleased to announce that the parties have agreed that all the contractual conditions precedent necessary to implement the acquisition of the API Business have now been met. The API Business has been transferred to Aspen with effect from today's date.
30-Sep-2013
(Official Notice)
Following the publication of this announcement, shareholders are advised that caution is no longer required to be exercised when dealing in Aspen securities.



30-Sep-2013
(Official Notice)
13-Sep-2013
(Official Notice)
Aspen confirm that, following a very successful senior syndication of the USD2 035 000 000 acquisition finance facilities for Aspen Global Incorporated (AGI or the Borrower) a 100% owned subsidiary of Aspen, Bank of America Merrill Lynch and The Standard Bank of South Africa Ltd (SBSA) (together the Initial Mandated Lead Arrangers and Bookrunners) have now launched the transaction into general syndication.



Prior to the launch of general syndication, and as a result of a very successful senior syndication, those banks that committed as sub-underwriters had their allocations scaled back to the requested final hold commitments. During senior syndication Absa Bank Limited, BNP Paribas, Nedbank Limited, The Royal Bank of Scotland plc, Standard Chartered Bank committed as Non-Active Bookrunners and Mandated Lead Arrangers; FirstRand Bank Limited as a Senior Lead Arranger; and Investec Bank Limited, National Australia Bank Limited and The Bank of Tokyo-Mitsubishi UFJ Ltd. as Senior Arrangers.



The Facilities which were partially underwritten by the Initial Mandated Lead Arrangers will be used to (i) support AGI's previosuly announced potential acquisition of product portfolios from Merck - Co, GlaxoSmithKline as well as two other pre-identified acquisitions; and (ii) refinance all of AGI's existing term bank debt.



With respect to the syndication of the ZAR7 330 000 000 facilities for Pharmacare Limited (a 100% owned subsidiary of Aspen) and Aspen, it is confirmed that commitments have been received and allocated on the ZAR funding, with significant support from the local ZAR Banking and Institutional market. The ZAR facilities were 132% oversubscribed resulting in scale back of the ZAR commitments. The oversubscription and subsequent scale back resulted in the ZAR sub-underwriting banks committing incremental liquidity to the USD denominated facilities.
13-Sep-2013
(Official Notice)
The total distribution payable, as announced on SENS on 11 September 2013, will be to shareholders recorded in the share register of the company as at the close of business on 11 October 2013.
11-Sep-2013
(C)
05-Sep-2013
(Official Notice)
Shareholders were referred to the cautionary announcement released by Aspen on 18 June 2013 (and subsequent renewals) in which shareholders were advised of discussions between Aspen and GlaxoSmithKline plc ("GSK") in respect of a possible transaction in terms whereof:

*Aspen Global Incorporated, a wholly owned subsidiary of Aspen, will acquire from GSK the Arixtra and Fraxiparine/Fraxodi brands ("the Brands") and business worldwide, except in China, Pakistan and India; and

*Aspen will acquire from GSK a specialised sterile production site which manufactures the Brands at Notre Dame de Bondeville, France ("the Site");

(collectively "the Proposed Transaction"); and

*Aspen's offer to GSK in respect of the Proposed Transaction is approximately GBP 700 million of which approximately GBP 100 million is for inventory.



Shareholders were advised that discussions regarding the Proposed Transaction remain ongoing and may have a material effect on the price of Aspen's securities if successfully concluded and accordingly shareholders are advised to continue exercising caution when dealing in Aspen's securities.
30-Aug-2013
(Official Notice)
Aspen shareholders were advised that diluted normalised headline earnings per share ("DNHEPS") from continuing operations, headline earnings per share and earnings per share for the 12 months ended 30 June 2013 are expected to exceed those reported in the comparative period, ended 30 June 2012, within the following ranges:

*DNHEPS from continuing operations -- 26% to 33%

*Headline earnings per share -- 16% to 23%

*Earnings per share -- 16% to 23%



Aspen's audited results for the 12 months ended 30 June 2013 are scheduled to be published on SENS on 11 September 2013.
07-Aug-2013
(Official Notice)
24-Jul-2013
(Official Notice)
Shareholders are referred to the cautionary announcement released by Aspen on 18 June 2013 in which shareholders were advised of discussions between Aspen and GlaxoSmithKline plc ("GSK") in respect of a possible transaction in terms whereof:

* Aspen Global Incorporated, a wholly owned subsidiary of Aspen, will acquire from GSK the Arixtra and Fraxiparine/Fraxodi brands ("the Brands") and business worldwide, except in China, Pakistan and India; and

* Aspen will acquire from GSK a specialised sterile production site which manufactures the Brands at Notre Dame de Bondeville, France ("the Site"). (collectively "the Proposed Transaction").



Aspen and GSK have agreed to make known the value of the Proposed Transaction in the interests of providing clarity to stakeholders on a matter which has been the subject of speculation. Aspen's offer to GSK in respect of the Proposed Transaction is approximately GBP700 million of which approximately GBP100 million is for inventory.



Shareholders are advised that discussions regarding the Proposed Transaction remain ongoing and may have a material effect on the price of Aspen's securities if successfully concluded and accordingly shareholders are advised to continue exercising caution when dealing in Aspen's securities.
27-Jun-2013
(Official Notice)
Shareholders are referred to the cautionary announcement released on SENS on 18 June 2013 wherein Aspen and Aspen Global Incorporated are currently engaged in discussions with GlaxoSmithKline Plc and are advised to continue to exercise caution when dealing in Aspen securities until a further announcement is made in respect thereto.
27-Jun-2013
(Official Notice)
19-Jun-2013
(Media Comment)
Business Report highlighted that South Africa leading generic drug manufacturer Aspen Pharmcare has made an offer to buy two of GlaxoSmithKline's (GSK) branded thrombosis medicines, Arixtra and Fraxiparine, as well as a manufacturing facility. The two medicines which are used for the treatment of blood clots during operations had global sales of GBP420 million (R7 billion) last year.
18-Jun-2013
(Official Notice)
Shareholders are advised that Aspen and Aspen Global Incorporated (AGI- a wholly owned subsidiary of Aspen) are currently engaged in discussions with GlaxoSmithKline plc (GSK) in respect of a possible transaction. Aspen and AGI have made a combined offer to GSK in terms whereof:

*AGI will acquire from GSK the Arixtra and Fraxiparine/Fraxodi brands (the Brands) and business worldwide, except in China, Pakistan and India - these Brands generated approximately GBP420 million in revenue for GSK in its 2012 financial year ended 31 December 2012. The Brands would transfer to AGI at the end of 2013; and

*Aspen will acquire from GSK a specialised sterile production site which manufactures the Brands at Notre Dame de Bondeville, France (the Site). The Site would transfer to Aspen during the fourth quarter of Aspen's 2014 financial year.



The conclusion of the Proposed Transaction will be subject to GSK's acceptance of the offer, consultation with affected GSK employees, certain regulatory approvals and approval by Aspen's shareholders. Accordingly shareholders are advised to exercise caution when dealing in the company's securities until a further announcement in this regard is made.
03-Jun-2013
(Official Notice)
Shareholders are referred to the cautionary announcement released by Aspen on 4 February 2013 (and subsequent renewals of this cautionary announcement) in which shareholders were advised of discussions between Aspen and MSD, known as Merck in the United States and Canada, in respect of a possible transaction comprising the acquisition of an active pharmaceutical ingredient facility situated primarily in the Netherlands and a related portfolio of pharmaceutical finished dose form products.



These discussions remain ongoing and may have a material effect on the price of Aspen?s securities if successfully concluded and accordingly shareholders are advised to continue exercising caution when dealing in Aspen's securities.
23-Apr-2013
(Official Notice)
Shareholders are referred to the renewal cautionary announcement released by Aspen on 7 March 2013 in which shareholders were advised of discussions between Aspen and MSD (known as Merck in the United States and Canada) in respect of a possible transaction comprising the acquisition of an active pharmaceutical ingredient facility situated primarily in the Netherlands and a related portfolio of pharmaceutical finished dose form products.



These discussions remain ongoing and may have a material effect on the price of Aspen's securities if successfully concluded and accordingly shareholders are advised to continue exercising caution when dealing in Aspen's securities.
18-Apr-2013
(Official Notice)
07-Mar-2013
(C)
21-Feb-2013
(Official Notice)
Aspen shareholders are advised that, diluted normalised headline earnings per share ("DNHEPS") from continuing operations, headline earnings per share and earnings per share for the 6 months ended 31 December 2012, are expected to exceed those reported in the comparative period, ended 31 December 2011, within the following ranges:

* DNHEPS from continuing operations: 21% to 25%

* Headline earnings per share: 15% to 19%

* Earnings per share: 5% to 9%



Aspen's interim results for the 6 months ended 31 December 2012 are scheduled to be published on SENS on 7 March 2013.
04-Feb-2013
(Official Notice)
Shareholders are advised that Aspen is currently engaged in discussions with MSD (known as Merck in the United States and Canada) in respect of a possible transaction comprising the acquisition of an active pharmaceutical ingredient facility situated primarily in the Netherlands and a related portfolio of pharmaceutical finished dose form products.



These discussions may have a material effect on the price of Aspen's securities if successfully concluded and accordingly shareholders are advised to exercise caution when dealing in the company's securities.
19-Dec-2012
(Media Comment)
Business Day highlighted that Aspen Pharmcare rose 5.14% to R167 after GlaxoSmithKline won US approval for a new flu vaccine. Aspen recently acquired distribution rights in Australia for a portfolio of 25 GlaxoSmithKline pharmaceutical products
04-Dec-2012
(Official Notice)
Shareholders are advised that at the annual general meeting of Aspen shareholders held on Tuesday, 4th December 2012, the ordinary and special resolutions proposed in terms of the notice of annual general meeting dated 22 October 2012 were all passed by the requisite majorities.
03-Dec-2012
(Official Notice)
Shareholders are referred to the Aspen Holdings SENS announcement of 15 August 2012 in which shareholders were advised that Aspen Global Incorporated (Aspen Global), a wholly owned subsidiary of Aspen Holdings, had reached agreement with GlaxoSmithKline plc (GSK) for the acquisition of a portfolio of 25 established pharmaceutical products (the Products) distributed in Australia (the Transaction).



The transaction was subject to the following conditions precedent:

*The approval of the Australian competition authorities; and

*The approval of the Australian Foreign Investment Review Board.



Aspen Holdings is pleased to announce that both these conditions precedent have been met and that the transaction has, as a result, been completed with effect from 30 November 2012. Shareholders are further advised that the final consideration in respect of the transaction has reduced from GBP 172.0 million to GBP 163.8 million. This reduction was due to the completion of the transaction being subject to one of the pharmaceutical products originally included in the transaction being excluded and the completion of the transaction being delayed beyond 31 October 2012.
05-Nov-2012
(Official Notice)
Shareholders were advised that the Annual Report for the year ended 30 June 2012 was posted on 5 November 2012.



Shareholders were advised that the values for tangible asset capital expenditure commitments disclosed under note A of the group supplementary information as published in the preliminary results released on SENS 12 September 2012 were understated as a result of an omission identified during the completion of the final annual report process in one of Aspen's subsidiary companies. "Contracted and authorised tangible assets commitments" is greater by R77m with a revised total of R158.8m and "Authorised but not contracted tangible assets commitments" is greater by R111.4m with a revised total of R456.4m. The understatements did not in any way affect the earnings per share, headline earnings per share or the normalised diluted headline earnings per share from continuing operations, adjusted for transaction and restructure costs, the statement of financial position and the statement of cash flow as published in the preliminary results released on SENS 12 September 2012.



The annual financial statements were audited by PricewaterhouseCoopers Inc. Their unqualified report is available for inspect at the company's registered office.



Notice of annual general meeting

Notice was given that the annual general meeting of shareholders of Aspen will be held on Tuesday, 4 December 2012 at 09:00 at Building 1, Healthcare Park, Woodlands Drive, Woodmead to transact the business stated in the notice of annual general meeting, which notice forms part of the annual report.
12-Sep-2012
(C)
05-Sep-2012
(Official Notice)
Shareholders are referred to the announcement released on 7 June 2012 wherein it was confirmed that:

*in order to facilitate the redemption of certain funding obligations, Imithi Investments (Pty) Ltd had concluded a process of disposing of 9 839 276 Aspen ordinary shares, as allowed for in terms of the agreements governing the BEE transaction between Aspen and Imithi (the details of which were more fully disclosed in the announcement released on 7 June 2012);

*17 600 000 new variable rate, voting, convertible, redeemable, cumulative A preference shares would be converted into 17 600 000 ordinary shares (New Aspen Ordinary Shares); and

*Aspen would apply for the listing of the New Aspen Ordinary Shares in Imithi?s name on the Main Board of the JSE. This listing took effect on 28 June 2012.



Collectively referred to as the Sale and Conversion Process.



Following the finalisation of the Sale and Conversion Process, Imithi now holds 21 160 724 Aspen ordinary shares representing 4.65% of Aspen Shares in issue. As a further result of this Sale and Conversion Process and subsequent transactions between the shareholders of Imithi, Dr N J Dlamini, Aspen?s non-executive Chairman now holds an indirect beneficial interest in 2 626 850 Aspen ordinary shares.
30-Aug-2012
(Official Notice)
Aspen's shareholders are hereby advised that diluted normalised headline earnings per share from continuing operations, headline earnings per share ('HEPS") and earnings per share, for the 12 months ended 30 June 2012, are expected to exceed those reported in the comparative period, ended 30 June 2011, by the following ranges:

*Diluted normalised HEPS from continuing operations is expected to be up between 18% and 24%

*HEPS is expected to rise between 21% to 27%

*Earnings per share be netween 4% to 10% higher

Aspen's audited results for the year ended 30 June 2012 are scheduled to be published on SENS on 12 September 2012.
15-Aug-2012
(Official Notice)
07-Jun-2012
(Official Notice)
20-Apr-2012
(Official Notice)
09-Mar-2012
(Official Notice)
The Aspen board of directors announce that Mr Kuseni Dlamini has been appointed to the board as an independent non- executive director with effect from 1 April 2012.
07-Mar-2012
(C)
21-Feb-2012
(Official Notice)
Aspen shareholders are hereby advised that earnings per share, for the 6 months ended 31 December 2011, are expected to exceed those reported in the comparative period, ended 31 December 2010, by 24% to 30%. The growth in earnings per share has benefited from the disposal of the discontinued businesses and products. Headline earnings per share and diluted normalised headline earnings per share from continuing operations, adjusted for transaction and restructure costs are both expected to exceed those of the comparative period by 17% to 23%. Aspen's interim results are scheduled to be published on SENS on 7 March 2012.
01-Dec-2011
(Official Notice)
Shareholders are advised that at the annual general meeting of Aspen shareholders held on Thursday, 1 December 2011, the ordinary and special resolutions proposed in terms of the notice of annual general meeting dated 21 October 2011 were all passed by the requisite majorities. The board of directors announce the appointment of Mr Riaan Verster as company secretary and Group Governance Officer with effect from 1 December 2011.
01-Dec-2011
(Official Notice)
Bloomberg's reported after Aspen's Annual General Meeting (AGM) this morning:

"Aspen Pharmacare Holdings Ltd., the largest maker of generic drugs in the Southern Hemisphere, said a strike by workers in South Africa during its first half will have a "fairly severe" impact on earnings. Aspen Chief Executive Officer Stephen Saad commented at the company's annual meeting of shareholders in Johannesburg today."



This report is a consequence of a statement made by Stephen Saad, Aspen's Group Chief Executive Officer, in response to a question from a shareholder at the AGM. To clarify this matter, Aspen wishes to advise that Mr. Saad told shareholders in attendance that it was extremely difficult to evaluate the financial consequences of the strike, given that some of the production lost had subsequently been recovered and sales lost during the period of the strike would have, at least, been partially recovered.

Mr. Saad furthermore mentioned ZAR40 million in order to give context to the possible effect of the strike on operating profits. Investors were alerted to the fact that the strike had impacted performance at the final results presentations made in September 2011 and in the annual report published early in November 2011.
02-Nov-2011
(Official Notice)
Shareholders are advised that the Annual Report for the year ended 30 June 2011 was posted on 2 November 2011. The annual financial statements contain no modifications to the reviewed preliminary results which were published on SENS on 13 September 2011 and the financial press on 14 September 2011. The annual financial statements were audited by PricewaterhouseCoopers Inc. Their unqualified report is available for inspect at the company's registered office.



Notice is hereby given that the annual general meeting of shareholders of Aspen will be held on Thursday, 1 December 2011 at 09:30 at Building 1, Healthcare Park, Woodlands Drive, Woodmead to transact the business stated in the notice of annual general meeting, which notice forms part of the annual report.



13-Oct-2011
(Official Notice)
The Aspen board of directors advised that Mr David Nurek has confirmed his retirement from the board with effect from 1 December 2011, as he will not be making himself available for re-election at Aspen's annual general meeting scheduled for that date.
13-Sep-2011
(Official Notice)
13-Sep-2011
(C)
02-Sep-2011
(Official Notice)
Aspen shareholders were advised that earnings per share, for the twelve months ended 30 June 2011, are expected to exceed those reported in the comparative period, ended 30 June 2010, by 18% to 22%. Headline earnings per share is expected to be below this range. Headline earnings per share from continuing operations, adjusted for transaction and restructure costs mainly related to the acquisition of the pharmaceutical division of Sigma Pharmaceuticals Ltd in Australia, is expected to exceed those of the comparative period by 18% to 22%. Aspen's results are scheduled to be published on SENS on 13 September 2011.
15-Aug-2011
(Official Notice)
In compliance with Section 3.59 of the Listings Requirements of the JSE Limited, the board of directors announce that following the resignation of Ramani Naidoo from the position of company secretary with effect from 12 August 2011, the previous incumbent in this position, Mr Hymie Aaron Shapiro has been re-appointed as company secretary with effect from the same date and will remain in this position whilst a full-time replacement for this position is recruited.
05-Aug-2011
(Official Notice)
The company advised that Ms Ramani Naidoo has tendered her resignation as company secretary and group governance officer with effect from 12 August 2011. A further announcement will be made once a new company secretary has been appointed.
24-Mar-2011
(Media Comment)
Business Report noted that Aspen was upgraded to overweight by Morgan Stanley. The investment bank believes that opportunities were not reflected in the share price. London-based analysts, Simon Mather and Peter Verdult, wrote that the recent 25% sell-off is overdone and "offers investors an excellent entry point into the name."
04-Mar-2011
(Official Notice)
Aspen announced the appointment of Ms Ramani Naidoo as company secretary and group governance officer with effect from 3 March 2011. Ms Naidoo takes over from Mr Hymie Shapiro, who retires from this role to pursue other executive responsibilities within Aspen.
03-Mar-2011
(Official Notice)
03-Mar-2011
(Official Notice)
03-Mar-2011
(C)
17 Jan 2011 07:58:56
(Media Comment)
According to Business Day, Aspen Pharmacare CEO Stephen Saad has dismissed a warning by Australian Sigma Pharmaceuticals that government regulation on medicine prices would knock revenue generated by the company, which is selling its generic drug business to Aspen for R6.1 billion. The deal will come into effect on January 31, and will make Aspen the biggest Australian pharmaceutical company by prescription volumes. Much as the Department of Health in SA has done, the Australian government has introduced reforms that stop pharmaceutical companies from giving pharmacies and hospitals perverse incentives such as rebates and bonuses and requires them to declare their wholesale prices. The federal government expects the reforms will save USD1.9 billion on prescription drugs over the next five years. Mr Saad said Aspen was not worried about the regulations, as this was a feature of Pharmaceutical markets around the world. HE said the bigger issue facing Sigma was its cost of procurement. "Regulations come, they go, they change . It's something I've learnt to live with. You need to fix your business so that you can compete," he said on Friday.
14 Jan 2011 09:15:23
(Official Notice)
Aspen shareholders are referred to the announcements released on the Securities Exchange News Service of the JSE Limited on 16 August 2010 and 23 November 2010, respectively, wherein, Aspen announced that the Aspen Group had reached formal agreement with Sigma to acquire the pharmaceutical business of Sigma on a debt- free basis for a cash consideration of AUD900 million (approximately ZAR 6 148 million at current exchange rates) ("the Transaction"), and that the Transaction was subject to a number of conditions precedent.



Aspen announce that, following approval of the transaction received at the extraordinary General Meeting of Sigma's Shareholders, held on 14 January 2011, all the conditions precedent to the Transaction have now been met and the Transaction is now unconditional. The Transaction is scheduled to complete on 31 January 2011.
14 Dec 2010 10:28:11
(Official Notice)
Following the announcement of the anti-retroviral ("ARV") tender results by the South African National Treasury Department, Aspen announced that it has been successful in winning a number of key products in the tender, including Efavirenz and Tenofovir, in spite of strong competition. The tender is effective for a period of two years, commencing 01 January 2011. Aspen secured approximately 40% of the awarded tender value based upon expected future demand as published in the invitation to tender. The tender value is estimated to be R3.6 billion over two years. The South African ARV tender is the largest of its kind in the world. Aspen has been a leading supplier to this tender since inception of the programme, providing a consistent and reliable supply of high-quality ARV products to the state.



Aspen's range of ARV's are produced at its world-class manufacturing facilities in Port Elizabeth, South Africa. The Group has invested more than R2 billion over the last five years in extending its manufacturing capability and enhancing the existing facilities. This has resulted in unlocking capacity to accommodate growing demand from Aspen's domestic and foreign territories and also contributed towards further optimising manufacturing efficiencies. Aspen's portfolio of ARV's supports close to 900 000 patients in South Africa daily.
26 Nov 2010 14:04:21
(Official Notice)
Shareholders are advised that at the annual general meeting of Aspen shareholders held on Friday, 26 November 2010, the ordinary and special resolutions proposed in terms of the notice of annual general meeting dated 21 October 2010 were all passed by the requisite majorities. The special resolution will be submitted to CIPRO for registration.
23 Nov 2010 08:58:24
(Official Notice)
Aspen shareholders were referred to the announcement released on SENS on 16 August 2010 wherein Aspen announced that Aspen had agreed in principle to acquire the pharmaceutical business conducted by Sigma on a debt-free basis for a cash consideration of AUD900 million (approximately R6 228 million at current exchange rates) ("the transaction").



Aspen has now reached formal agreement with Sigma on the terms and conditions of the transaction and the ongoing relationship between the two companies. The transaction is subject to a number of conditions precedent, including Sigma shareholder, Sigma lender and Australian regulatory approval. It is anticipated that Sigma will hold an extraordinary general meeting for the purposes of Sigma's shareholders considering the transaction in mid-January 2011. Subject to satisfaction of the conditions precedent, the transaction is scheduled to conclude on 31 January 2011.
03 Nov 2010 13:31:09
(Official Notice)
Shareholders are advised that the annual report for the year ended 30 June 2010 was posted on 3 November 2010 The annual financial statements contain no modifications to the reviewed preliminary results which were published on SENS on 15 September 2010 and the financial press on 16 September 2010.



Notice of AGM

Notice was given that the annual general meeting of shareholders of Aspen will be held on Friday, 26 November 2010 at 09:30 at Building 1, Healthcare Park, Woodlands Drive, Woodmead to transact the business stated in the notice of annual general meeting, which notice forms part of the annual report.
28 Oct 2010 09:05:06
(Media Comment)
Business Day reported that Australia's Competition watchdog has delayed until 25 November 2010 a decision on Aspen's AUD900 million bid for Sigma Pharmaceuticals' ("Sigma's") generic drugs division, after raising concern about dominance in some product lines. The main concern in the Aspen-Sigma deal is the combined business's control of the injectable polymaltose drugs Ferrum H and Ferrosig, which will give Aspen complete dominance in this market if the deal goes ahead. Analysts seemed unconcerned though, saying the final decision is unlikely to stop the merger.
16 Sep 2010 09:30:11
(Media Comment)
Business Day reported that SA's biggest drug maker, Aspen Pharmcare said its new strategy of pushing private sector sales in Latin America had borne fruit, and was steering the unit back towards profitability. Aspen's latin American business, which is dominated by its Brazilian operations, reported revenue of R1.2 billion for the year ended 30 June 2010, a significant improvement on the first six months of the year when the company reported R500 million. CEO Stephen Saad commented that this is the most exciting territory for Aspen. Aspen deputy CEO Gus Attridge indicated the group was looking at expansion opportunities in Asia.



15 Sep 2010 14:36:45
(C)
Revenue for the period increased by 20% to R10.1 billion (2009: R8.4 million) . Gross profit improved by 19% R4.6 billion (2009: R3.9), while operating profit rose to R2.6 billion (2009: R2.1 billion). Profit for the year attributable to equity holders of the parent jumped to R1.9 billion (2009: R1.3 billion). Furthermore, headline earnings per share from total operations soared to 482.9cps (2009: 389.4cps).



Dividend

Notice is hereby given that, in terms of a general authority to distribute the company's capital granted by shareholders at the annual general meeting held on 4 December 2009, a capital distribution of 70 cents per ordinary share (2009: zero) by way of a capital reduction has been declared, payable out of share premium to shareholders.



Prospects

The addition to Aspen's business in South Africa of the GSK brands and the people who promote and support these brands has served to strengthen the group's national leadership in pharmaceuticals. Aspen has the most extensive product offering, the greatest representation and is the biggest supplier of pharmaceuticals in the private and public sectors. The business is supported by a substantial product pipeline and manufacturing facilities which are the most advanced as well as offering the largest capacity in the southern hemisphere. The fundamental dynamics of South Africa indicate a sustained increase in demand for medicines. Aspen's South African pharmaceutical business is well set to continue to thrive, assisted by the recent period of regulatory stability and government's stated intention to support the local pharmaceutical industry. The difficult trading environment in South Africa for consumer products has necessitated a focus on efficiency of structures which should stand Aspen in good stead when the retail cycle improves. Initiatives being undertaken in the sub-Saharan African region should result in an increased contribution to group profits in the year ahead. An upswing in results in Latam, continued organic growth in Asia Pacific and the benefit of a full year of contribution from the global brands acquired over the last year will be growth drivers for the international business in the year ahead. Completion of the acquisition of the Sigma pharmaceutical business will add further growth momentum. The group has the fundamentals in place to enjoy a 13th consecutive year of uninterrupted real growth in 2011.
23 Aug 2010 11:43:00
(Official Notice)
Aspen shareholders are hereby advised that headline earnings per share, for the twelve months ended 30 June 2010, are expected to exceed those reported in the comparative period, ended 30 June 2009, by 20% to 25%. Earnings per share are anticipated to exceed those of the comparative period by 30% to 35%. The lower increase in headline earnings per share is caused by the exclusion of non-recurring capital profits and losses in the determination thereof. The group's South African business has been the leading contributor to the growth recorded. Aspen's results are scheduled to be published on SENS on 15 September 2010.
16 Aug 2010 08:11:52
(Official Notice)
Aspen shareholders are referred to the detailed cautionary announcement released on SENS on 21 May 2010, and to the related renewal and further cautionary announcements dated 7 July 2010 and 12 July 2010, respectively ("cautionary announcements"). Subsequent to the completion by Aspen of the due diligence process referred to in the cautionary announcements, Aspen Global Inc ("Aspen Global"), a 100% owned subsidiary of Aspen, submitted, to the board of directors of Sigma ("Sigma board"), an offer ("subsequent offer") to acquire the pharmaceutical business conducted by Sigma ("pharmaceutical business") on a debt-free basis for a cash consideration of AUD900 million (approximately AR5 871 million). The subsequent offer, which the Sigma board has undertaken to support, is subject to limited conditions precedent as detailed below.



Effective date

The effective date of the implementation of the subsequent offer will be upon completion of the conditions precedent.



Conditions precedent

The completion of the subsequent offer is subject to the satisfactory conclusion of limited conditions precedent which are normal for a transaction of this nature, including:

*conclusion of a business and/or share purchase agreement between Aspen and Sigma;

*all requisite regulatory approvals; and

*the approval of Sigma shareholders.



Categorisation and withdrawal of cautionary

An announcement has been released today in terms of the ASX regulations by Sigma and is available at the ASX website at www.ASX.com.au. The subsequent offer has been classified as a category two transaction in terms of section 9.5(a) of the JSE Ltd Listings Requirements. The cautionary announcement dated 12 July 2010 is hereby withdrawn. Accordingly, Aspen shareholders are no longer required to exercise caution when dealing in Aspen shares.
12 Jul 2010 09:55:01
(Official Notice)
Aspen shareholders are referred to the renewal of detailed cautionary announcement dated 7 July 2010 regarding the confirmed offer (the "offer") by Aspen Global Incorporated to acquire the whole of Sigma Pharmaceuticals Ltd ("Sigma"). The board of directors of Sigma has advised Aspen that it will work constructively with Aspen to eliminate the need for the current conditions to which the offer is subject. To this extent, Aspen shareholders are referred to the announcement released today by Sigma, which is available on the ASX website www.asx.com.au. Aspen shareholders are advised to continue to exercise caution when dealing in Aspen shares until a further announcement is made.
07 Jul 2010 09:00:43
(Official Notice)
Aspen shareholders are referred to the detailed cautionary announcement dated 21 May 2010 and are advised that Aspen Global Incorporated ("Aspen Global") has submitted to Sigma Pharmaceuticals Ltd ("Sigma"), a confirmed offer to acquire the whole of Sigma (the transaction") for cash at a price per Sigma share of AUD0.55 (approx. ZAR3.58)1 (the "Offer") which implies an equity value of AUD648 million (approx. ZAR4 219 million)1 based on 1,178.6 million Sigma shares outstanding. Aspen has proposed that the transaction be executed via a scheme of arrangement.



The offer is also subject to numerous conditions precedent, including the satisfactory completion by Aspen of a final due diligence investigation, the conclusion of a scheme implementation agreement and fulfilment of all necessary regulatory approvals. Aspen shareholders are referred to the announcement released today by Sigma, which is available at the ASX website www.asx.com.au. Accordingly, Aspen shareholders are advised to continue to exercise caution when dealing in Aspen shares until a further announcement is made.

06 Jul 2010 07:24:22
(Media Comment)
Business Day reported that Aspen will lower its USD594 million takeover offer for Australia's Sigma Pharmaceuticals ("Sigma") after completing a review of the company's accounts. Aspen has also held talks with Sigma about the business and discussions, which hinge on the offer price, are continuing. A final price will balance Sigma's funding needs and Aspen's desire to make a return on any acquisition. Sigma's share price has remained below Aspen's AUD0.60 per share offer.
17 Jun 2010 09:31:00
(Media Comment)
Following a takeover bid of Sigma by Aspen, Sigma has named its former chief financial officer to its top job despite posting a record loss. According to Business Report, Mark Hooper is due to start as chief executive of Sigma in September 2010. Sigma rose by 3.1 percent in Sydney on 16 June 2010.
24 May 2010 09:25:29
(Media Comment)
Business Day indicated that Aspen Pharmcare would acquire troubled Australian drug maker Sigma Pharmaceuticals for USD570 million to bolster its presence in the fast- growing generic drug market. Sigma the largest player in Australia's drug industry, has recently been plague by difficulty. It booked a hefty annual loss and its chairman, CEO, and chief financial officer all left the company last month. Aspen, Africa's largest pharmaceutical firm, is one of the world's top 20 manufacturers of generic drugs and has had a presence in Australia since 2001. Investment bank Lazard has been hired to advise Sigma, while Investec is advising Aspen.
21 May 2010 10:31:19
(Official Notice)
Aspen shareholders are advised that Aspen has submitted an indicative non- binding proposal to acquire, either directly or through a wholly-owned subsidiary, Sigma Pharmaceuticals Ltd at an enterprise value of AUD1.492 million (approx. ZAR 9,796 million), which implies a price per Sigma share of AUD0.60 (approx. ZAR3.94) (1) based on 1 178.6 million Sigma shares outstanding and net debt (including off-balance sheet facilities) of AUD785 million (approx. ZAR 5.154 million)1 as reported at 31 January 2010.



The proposal is currently envisaged to be executed by scheme of arrangement, but the transaction structure may be refined following due diligence. The proposal is also subject to numerous conditions precedent, including the satisfactory completion by Aspen of a due diligence investigation, fulfillment of all necessary regulatory approvals and the unanimous recommendation of any potential transaction by the Sigma board, and thus no formal agreement to enter into a transaction may result.



Aspen shareholders are referred to the announcement released by Sigma Pharmaceuticals Ltd, a company listed on the Australian Securities Exchange, which is available at the ASX website www.asx.com. If an offer is made, or transaction concluded it may have a material effect on the price at which Aspen?s shares trade on the JSE Ltd. Aspen shareholders are advised to exercise caution when dealing in Aspen shares until a further announcement is made.
23 Mar 2010 08:29:50
(Media Comment)
Business Report noted that Aspen will only fully realise the benefits of the 7.4% increase in the single exit price ("SEP") for medicines in the 2010/11 financial year as there are just three months left before the company completes the current financial year. Aspen has previously warned that the delay in releasing the SEP might tamper with its domestic growth in the second half of the current financial period.
19 Mar 2010 09:05:46
(Media Comment)
As reported in Business Report, Aspen has raked in more than double it's initial investment in an oncology joint venture after it sold it's 50% stake in the project, giving it extra cash to settle it's debt or pursue acquisitions. Aspen announced that it had sold it's half of the venture it started about two years ago with Strides Arcolab. The company sold it's stake to Strides for USD117 million (R854 million) following an initial investment of USD43 million in December 2007 when the firms established two joint ventures,Onco Therapies in India and Onco Laboratories in Cyprus.
18 Mar 2010 09:57:13
(Official Notice)
Aspen and Strides restructure Oncology arrangements Aspen Pharmacare Holdings Ltd ("Aspen"), and Strides Arcolab Ltd, announced a restructuring of their arrangements relating to the two oncology joint ventures between Aspen and Strides, Onco Therapies Limited ("OTL"), India and Onco Laboratories Ltd ("OLL"), Cyprus.



The following are the material terms of the restructuring:

*Aspen Global Incorporated will sell its 50% ownership in the Oncology JVs to Strides for a consideration of USD 117 million.

*Strides will license the existing and future oncology products to Pharmacare Limited, an Aspen Group company, for certain territories.

*The effective date of the above transactions is the first day of the month following the fulfillment of the conditions precedent which include, inter alia, the approval of the Exchange Control Department of the Reserve Bank of South Africa. *The payment terms are based upon certain future milestones with an outside date for settlement of all outstanding amounts by 30 April 2011.



The transactions signal the strategic intent of Aspen and of Strides in the oncology market. The transactions compliment Aspen's focus on sourcing differentiated products for supply through its international distribution network which reaches approximately 100 countries worldwide. Aspen already has a developing oncology business in most of these territories. Central to the Strides strategy is the enhancement of its manufacturing and development capabilities in its Specialties business. To this end, Strides has built capacities in facilities and development. This includes the establishment of world class sterile assets in India, Europe, the recent acquisition of the Campos facility in Brazil, and taking over full ownership of the Oncology JVs. The value of these assets has been demonstrated by the attraction of numerous leading pharmaceutical partners, including multinationals.
18 Mar 2010 09:01:42
(Official Notice)
Aspen Pharmacare Holdings Ltd ("Aspen"), and Strides Arcolab Ltd ("Strides'), announced a restructuring of their arrangements relating to the two oncology joint ventures between Aspen and Strides, Onco Therapies Ltd ("OTL"), India and Onco Laboratories Ltd ("OLL"), Cyprus.



The following are the material terms of the restructuring:

* Aspen Global Incorporated will sell its 50% ownership in the Oncology JVs to Strides for a consideration of USD 117 million;

* Strides will license the existing and future oncology products to Pharmacare Ltd, an Aspen Group company, for certain territories;

* The effective date of the above transactions is the first day of the month following the fulfilment of the conditions precedent which include, inter alia, the approval of the exchange control department of the Reserve Bank of South Africa;

* The payment terms are based upon certain future milestones with an outside date for settlement of all outstanding amounts by 30 April 2011.



Rationale

The transactions signal the strategic intent of Aspen and of Strides in the oncology market. The transactions compliment Aspen's focus on sourcing differentiated products for supply through its international distribution network which reaches approximately 100 countries worldwide. Aspen already has a developing oncology business in most of these territories. Central to the Strides strategy is the enhancement of its manufacturing and development capabilities in its specialties business. To this end, Strides has built capacities in facilities and development. This includes the establishment of world class sterile assets in India, Europe, the recent acquisition of the Campos facility in Brazil, and taking over full ownership of the Oncology JVs. The value of these assets has been demonstrated by the attraction of numerous leading pharmaceutical partners, including multinationals.
03 Mar 2010 15:19:29
(C)
12 Feb 2010 10:07:08
(Official Notice)
Aspen advised shareholders that earnings per share, and headline earnings per share, for the 6 months ended 31 December 2009, were anticipated to exceed those reported in the comparative period ended 31 December 2008, by between 20% and 30%. These results are supported by a strong performance from Aspen's South African business.
11 Dec 2009 15:04:07
(Official Notice)
Following GlaxoSmithKline's acquisition of an equity stake in Aspen, Abbas Hussain has been appointed to Aspen's board with effect from 7 December 2009. Abbas is GlaxoSmithKline's President: Emerging Markets. His extensive international pharmaceutical expertise will add value to Aspen.
04 Dec 2009 10:50:07
(Official Notice)
Shareholders are advised that at the annual general meeting held at 09:30 on Friday, 4 December 2009 the requisite majority of shareholders approved all ordinary and special resolutions as contained in the notice convening the general meeting. The special resolutions will be lodged for registration with CIPRO.
01 Dec 2009 09:09:21
(Official Notice)
Aspen informs shareholders that on 30 November 2009 the multiple strategic inter-dependant transactions between the Aspen group and the GlaxoSmithKline group ("GSK") were completed. Aspen allotted and issued 68.5 million ordinary shares to GSK in consideration for the transfer of assets on the same date.
03 Nov 2009 10:54:43
(Official Notice)
Further to the announcement issued on SENS on 12 May 2009, Aspen wishes to update shareholders on the status of completion of the multiple strategic inter - dependant transactions entered into between Aspen and GlaxoSmithKline Group ("GSK"). The conditions precedent to the agreement have been fulfilled. The completion date for the transaction will be 30 November 2009. Due to regulatory requirements, Aspen and GSK have agreed that:

*the transaction in terms of which Aspen's wholly-owned subsidiary, Aspen Global, will acquire eight specialist products from GSK will only be implemented in respect of Tanzania, Namibia and Zimbabwe upon approval from the Tanzanian, Namibian and Zimbabwean authorities, respectively.

*the Sub-Saharan collaboration transaction will only be implemented in respect of Tanzania, Namibia and Zimbabwe upon approval from the Tanzanian, Namibian and Zimbabwean authorities, respectively.

The portion of the purchase consideration payable to GSK for these territories is negligible and consequently there will be no adjustment to the purchase consideration as communicated to shareholders in the SENS announcement issued on 12 May 2009. It is expected that the consideration shares, comprising of 68.5 million ordinary shares in the share capital of Aspen, will be listed and issued to GSK on 30 November 2009.
03 Nov 2009 09:25:17
(Official Notice)
Notice is hereby given that the annual general meeting of shareholders of Aspen will be held on Friday 4, December 2009 at 09:30 at Building 1, Healthcare Park, Woodlands Drive, Woodmead to transact the business stated in the notice of annual general meeting, which notice forms part of the annual report.
08 Sep 2009 14:09:38
(C)
01 Sep 2009 10:30:05
(Official Notice)
Aspen shareholders are hereby advised that earnings per share, for the 12 months ended 30 June 2009, are forecast to exceed those reported in the comparative period, ended 30 June 2008, by 45% to 55%. Headline earnings per share are forecast to exceed those of the comparative period by 60% to 70%. The higher forecast increase in headline earnings per share is caused by the exclusion of non-recurring capital profits and losses in the determination thereof. Aspen's international operations, which have been significantly expanded over the past eighteen months, have contributed strongly to this growth whilst the South African operations have returned positive results, despite the challenging trading and economic environment. Having given consideration to Aspen's existing debt service commitments and future possible investments, the Aspen board of directors has resolved that there will be no cash distribution paid to shareholders this year. The financial results, on which this trading announcement is based, have not been reviewed or reported on by Aspen's external auditors. Aspen's results will be published on SENS on 8 September 2009.
30 Jul 2009 08:36:12
(Media Comment)
The Financial Mail reported that using 22 May 2008 as the start of the bear market, the JSE All Share Index ("Alsi") remains 27% down on its high as of the end of July 2009. However, Aspen, over the same period has gained 84%. The expansion of Aspen's product range and international operations as well its deal with the UK's GlaxoSmithKline have underpinned the steep rise in Aspen's share price, which is up 70% since the beginning of 2009, with its p:e rating increasing to 18.5. In addition, Aspen is now viewed alongside MTN Group Ltd and Naspers Ltd as emerging market growth stocks, and even though the share may look relatively fully priced, the rating indicates that investors could be expecting more strong growth.
15 Jul 2009 08:36:25
(Media Comment)
Business Day reported that Aspen has been ranked South Africa's top pharmaceutical company by a Campbell Belman survey for the fourth time in six years.
12 Jun 2009 16:40:33
(Official Notice)
14 May 2009 10:11:35
(Media Comment)
Aspen Pharmacare would add at least R721 million more to it's turnover following it's acquisition of eight specialist drugs from GlaxoSmithKline (GSK), it announced earlier this week. This amounts to the money the drugs generated for GSK in the year to December. The eight products include Alkeran, Leukeran and Purinethol, which are chemotherapy drugs used to treat cancer. Another is Kemadrin, used to relieve the symptoms of Parkinson's disease. Lanvis and Myleran treat Leukemia. Septrin is a broad-spectrum anti-microbial and Trandate is used for high blood pressure.



These drugs are going to be sold in worldwide markets except for Alkeran, which GSK is retaining in the US. The company said it would sell 44% in emerging markets, 36% in Europe, 8% in Australasia and Japan, and 12% in the US and Canada. The transactions are still subject to competition authorities and regulatory approvals.
12 May 2009 09:17:27
(Official Notice)
Further to the cautionary announcements issued on 13 January, 19 February and 26 March 2009, Aspen announces that it has agreed the terms to a series of strategic inter-dependent transactions with leading multinational pharmaceutical group, GlaxoSmithKline ("GSK"). The transactions comprise:

* the acquisition of the rights to distribute GSK products in South Africa by Aspen's wholly owned subsidiary, Pharmacare Ltd ("the SA component");

* the formation of a collaboration arrangement in relation to the marketing and selling of prescription pharmaceutical products in sub-Saharan Africa ("SSA") (excluding South Africa, Lesotho and Swaziland) between Aspen and GSK, to be known as "GSK Aspen Healthcare for Africa" ("the SSA Collaboration");

* the acquisition by a newly formed wholly-owned subsidiary of Aspen of GSK's manufacturing facility in Bad Oldesloe, Germany as a going concern ("the Facility"); and

* the acquisition by Aspen`s wholly-owned subsidiary, Aspen Global, of eight specialist products for worldwide distribution.

As consideration for the transactions, Aspen will issue 68.5 million ordinary shares to GSK (approximately 16% of Aspen's issued ordinary share capital after the issue thereof). On completion of the transaction GSK will attain the right to nominate one member to the Aspen board. Based on Aspen's closing share price on 11 May 2009, the transactions have a value of R3.47 billion, (USD411.5 million, GBP272.6 million). The final value of the transactions and the attribution of this value to the individual transactions will depend on the closing price of Aspen shares on the JSE Ltd upon completion of the transactions.
26 Mar 2009 10:48:09
(Official Notice)
Further to the cautionary announcement dated 13 January 2009, shareholders are advised that negotiations are still in progress which, if successfully concluded, may have a material effect on the price of Aspen's securities. Accordingly, shareholders are advised to continue exercising caution when dealing in Aspen's securities until a further announcement is made.
26 Mar 2009 09:14:38
(Media Comment)
GlaxoSmithKline plans to take a significant stake in Aspen to strengthen their partnership according to sources. The move, which could be announced in the next week or so, underlies Glaxo's commitment to growing in emerging markets as part of a strategy to diversify it's business.
13 Mar 2009 09:01:03
(Media Comment)
Business Report noted that Aspen, along with insurer Discovery Holdings Ltd, will be added to the JSE's Top40 index of blue chips. The companies replace Mondi plc and Sappi Ltd. Aspen has previously announced that it is involved in undisclosed talks, which has led to speculation that it could be a takeover target for GloxoSmithKline.
09 Mar 2009 11:43:46
(Media Comment)
Business Day reported that Aspen rose 6% on Friday, 6 March 2009, on the back of higher profits and comments by CEO Stephen Saad that the company hoped to have news on talks soon. GlaxoSimthKline is rumoured to be a prospective bidder.
05 Mar 2009 15:09:31
(C)
02 Mar 2009 10:30:12
(Official Notice)
Shareholders of Aspen are advised that Pasco Dyani has tendered his resignation as non-executive director of the board with effect from 26 February 2009.
19 Feb 2009 13:18:05
(Official Notice)
Further to the cautionary announcement dated 13 January 2009, shareholders are advised that negotiations are still in progress which, if successfully concluded, may have a material effect on the price of Aspen's securities. Shareholders are advised to continue exercising caution when dealing in Aspen's securities until a further announcement is made.
12 Feb 2009 14:55:14
(Official Notice)
Aspen shareholders are hereby advised that earnings per share, for the 6 months ended 31 December 2008, are forecast to exceed those reported in the comparative period ended 31 December 2007, by 45-60%. Headline earnings per share are forecast to exceed those of the comparative period by 65-80%. As anticipated, a strong contribution from Aspen?s recently expanded international operations has been the leading growth driver. The difference between the quantum of the anticipated percentage increase in earnings per share and in headline earnings per share is due to non-recurring capital profits being included in earnings per share in the comparative period. Aspen's results are expected to be published on SENS on 05 March 2009.
30 Jan 2009 13:30:50
(Official Notice)
Servier, a leading french, research-based pharmaceutical company and Aspen Pharmacare, the largest generics pharmaceutical manufacturer in the southern hemisphere, have signed a memorandum of understanding for the manufacture of Perindopril. Perindopril is primarily used for the treatment of hypertension and heart failure. In terms of this memorandum of agreement, Aspen will acquire the license to manufacture three Perindopril brands, CoversylRegistered, PrexumRegistered and VectorylRegistered. In terms of a technology transfer arrangement, scientific know-how will be transferred to Aspen, preceding intended commencement of manufacture at Aspen's South African-based facilities. This ground-breaking agreement is intended to secure the sustainable, effective, affordable and high- quality supply of this widely prescribed treatment into the South African market.
15 Jan 2009 08:15:15
(Media Comment)
Aspen Pharmacare Holdings announced on Tuesday,that it was in unspecified talks, that it is a potential takeover target for GlaxoSmithKline according to industry experts. Buying all or part of Aspen would mark a further step up in GSK chief executive Andrew Witty's drive to expand in emerging markets, where demand for medicines is now growing more quickly than in North America and Europe.Apen is Africa's largest pharmaceutical manufacturer. It is a major supplier of branded and generic drugs, healthcare and nutritional products in southern African and certain other markets. In July it stuck a ground breaking deal with GSK that paved the way for the British based drug maker to sell cheap branded generic medicines in emerging markets.GSK declined to comment on it's potential interest in Aspen.
13 Jan 2009 15:52:56
(Official Notice)
Shareholders of Aspen are advised that the company has entered into negotiations, which, if successfully concluded, may have a material effect on the price at which the company's securities trade. Accordingly, shareholders are advised to exercise caution when dealing in the company's securities until a further announcement is made.
28 Nov 2008 16:05:55
(Official Notice)
Shareholders are advised that at the annual general meeting held at 09:30 on Friday, 28 November 2008 the requisite majority of shareholders approved all ordinary and special resolutions as contained in the notice convening the general meting. The special resolutions will be lodged for registration with the Registrar of Companies.
07 Nov 2008 11:26:47
(Official Notice)
Shareholders are advised the company's annual financial statements for the year ended 30 June 2008 were distributed to shareholders on Thursday, 6 November 2008. The annual financial statements contain no modifications to the reviewed preliminary results which were published on SENS on 16 September 2008 and the financial press on 17 September 2008. The annual financial statements were audited by PricewaterhouseCoopers Inc Their unqualified report is available for inspection at the company's registered office.



The 2008 annual general meeting of shareholders of Aspen will be held in the Boardroom, building number 8, Healthcare Park, Woodlands Drive, Woodmead on Friday, 28 November 2007 at 09:30 to transact the business as stated in the notice of the annual general meeting.
16 Oct 2008 07:23:42
(Official Notice)
Shareholders are advised that Aspen Global Inc ("Aspen Global"), a wholly owned subsidiary of Aspen, has concluded a five-year US dollar denominated funding arrangement for an amount of USD385 million with a consortium of banks. This funding has replaced a bridging loan from the Standard Group which was raised primarily to settle Aspen Global's liability of GBP170 million to GlaxoSmithKline ("GSK") arising from the acquisition of four branded products from GSK. The funding arrangement which was executed on 10 October 2008, comprises of:

*A 5-year amortising loan of USD255 million, with a 1-year capital repayment holiday

*A 5-year non-amortising loan of USD130 million. Repayments may be made on this loan out of free cash flow.

The cost of this debt has been fixed at an all in rate of 6.11% per annum over 90%of its term (which takes account of prepayments) by Aspen Global entering into an interest rate swap transaction as follows:

*100% cover of interest payments over the first 3 years of the loans

*83% cover of interest payments over the 4th year of the loans

*66% cover of interest payments over the 5th year of the loans.

The interest payments remaining unhedged, bear interest at a rate of 3-month USD LIBOR plus a margin of 2.8%. The above arrangements are considered to be favourable, given current global financial markets.
09 Oct 2008 10:08:41
(Official Notice)
Aspen and Matrix Laboratories Ltd ("Matrix") of the Republic of India, would like to announce the divestment of the existing joint ventures relating to the two chemical-manufacturing entities, Fine Chemicals Corporation (Pty) Ltd ("FCC") in Cape Town, South Africa and Astrix Laboratories ("Astrix") Ltd in Hyderabad, India. Aspen will acquire 50% of FCC from Matrix and, in turn, dispose of its 50% share in Astrix to Matrix. Aspen will retain a shareholding in Astrix through a B-share. Aspen and Matrix have secured a long-term supply agreement for the continued supply of anti-retroviral ("ARV") active pharmaceutical ingredients. Furthermore, Aspen has acquired the rights to distribute a number of new generation ARV combination products into the South African and African markets.
16 Sep 2008 13:47:33
(C)
16 Sep 2008 12:06:20
(Official Notice)
Further to the announcement made on 20 November 2007, Aspen announced that its wholly owned subsidiary, Aspen Global Incorporated ("Global") has agreed revised terms with Strides Arcolab Ltd ("Strides"), a pharmaceutical company registered in the Republic of India, in respect of certain aspects of Global`s acquisition of an interest in Strides` Latin American operations. The revised terms provide for the acquisition of a further 1% in the Latam Operations with immediate effect as well as a revision of the put and call options previously concluded.
09 Sep 2008 08:21:09
(Media Comment)
According to Business Report, Aspen might discontinue making certain antibiotics. Group CE Stephen Saad said that production will end if Aspen is not granted the price increases it has requested from the health department.
26 Aug 2008 11:09:59
(Official Notice)
Shareholders are advised that Roy Andersen has been appointed to the board of directors of Aspen as an independent non-executive director with effect from 26 August 2008.
23 Jul 2008 09:06:35
(Official Notice)
Aspen announced that it has entered into licensing and supply agreements with leading multinational pharmaceutical corporation, GlaxoSmithKline ("GSK"). In terms of the agreements Aspen will license intellectual property and supply finished dosage form pharmaceuticals to GSK through Aspen Group companies including Onco Therapies Ltd ("OTL"), Aspen's 50% owned joint venture with Strides Arcolab Ltd ("Strides") of India.



The licensing and supply agreements are for emerging market territories excluding Sub-Saharan Africa and India. Aspen and OTL will recover intellectual property development costs from GSK in addition to sharing profits with GSK from the commercialisation of the products. The first of the products commercialised under this arrangement is expected to be launched in 2010.
16 Jul 2008 09:31:27
(Official Notice)
Aspen shareholders are referred to the cautionary announcement dated 6 June 2008, and the subsequent announcement dated 30 June 2008, relating to the worldwide acquisition of brands by Aspen Global Incorporated. As a result of those announcements, shareholders of Aspen are accordingly no longer required to exercise caution when dealing in their Aspen shares.
30 Jun 2008 14:27:20
(Official Notice)
With reference to the cautionary announcement of 6 June 2008, Aspen is pleased to announce the conclusion of a deal by its wholly- owned subsidiary, Aspen Global Incorporated ("Global"), with leading multinational pharmaceutical company, GlaxoSmithKline (GSK), whereby Global has purchased the intellectual property rights to four post-patent originator products worldwide ("the GSK business"). The deal is valued at GBP170 million and is effective 1 July 2008.
26 Jun 2008 12:00:48
(Official Notice)
Aspen announced that its South African operating company has been successful in winning a significant portion of the Anti-Retroviral tender, in spite of strong competition. The tender is effective for a period of two years, commencing retrospectively from 01 June 2008.
06 Jun 2008 15:54:49
(Official Notice)
Shareholders of the company are advised that the company has entered into negotiations, which, if successfully concluded, may have a material effect on the price at which the company?s securities trade on the JSE. Accordingly, shareholders of the company are advised to exercise caution when dealing in the company?s securities until a further announcement is made.

05 May 2008 15:18:48
(Official Notice)
Aspen concluded a deal for the acquisition of 60% of the share capital of Shelys Africa Ltd, with operations in East and Central Africa with effect from 11 May 2008. Shelys Africa Ltd is the holding company of a group of East African pharmaceutical companies ("the Shelys Group"). The principal operations include Shelys Pharmaceuticals in Tanzania and Beta Healthcare International in Kenya. The Shelys Group reported consolidated revenue of USD38 million for 2007.
31 Mar 2008 14:55:56
(Official Notice)
The company announced the passing away of Mr Leslie Boyd on 27 March 2008. He was a non-executive director of Aspen. He also served as chairman on the company's remuneration committee.
25 Feb 2008 14:46:59
(C)
20 Feb 2008 10:16:36
(Official Notice)
Shareholders are hereby advised that, in view of his imminent immigration, Maxim Krok has tendered his resignation from the Aspen board with immediate effect.
19 Jul 2006 16:36:38
(Official Notice)
Aspen anticipates that headline earnings per share and earnings per share for the year ended 30 June 2006 will exceed those of the restated previous year ended 30 June 2005 (after adding back to earnings the R282.4 million charge in respect of the BEE transaction completed in June 2005), by between 25% and 35%. Headline earnings per share and earnings per share for the comparative year have been restated to comply with IFRS. Aspen's results are expected to be published on SENS on 21 August 2006
15 Jun 2006 16:36:13
(Official Notice)
Aspen shareholders are referred to the cautionary announcement dated 31 May 06 and are advised that the acquisition negotiations referred to therein, which related to the proposed offer by Aspen for all the issued and outstanding shares of Pliva d.d, have been terminated. Accordingly, caution is no longer required when dealing in the company"s securities.
31 May 2006 15:51:36
(Official Notice)
Shareholders of the company are advised that the company has entered into acquisition negotiations, which, if successfully concluded, may have a material effect on the price at which the company's securities trade on the JSE. Accordingly, shareholders of the company are advised to exercise caution when dealing in the company's securities until a further announcement is made.
16 May 2006 10:41:51
(Official Notice)
Aspen today announced that it has reached an agreement with Roche to produce a generic version of oseltamivir for Africa. This complements Roche's continued efforts to increase and speed up availability of the medicine for world wide influenza pandemic planning. The agreement focuses on providing oseltamivir for pandemic use to further help to address the needs of governments and other not for profit organisations in the African sub - continent. Roche will provide technical know how (technical, pre-clinical and clinical data) to assist Aspen to help them expedite their production and the registration. The agreement also allows the supply of Active Pharmaceutical Ingredient (API) from Roche to Aspen.



Whilst Roche remains on schedule to meet all orders from African governments by early 2007, the collaboration with Aspen will further enhance the supply of oseltamivir for Africa. The agreement is non-exclusive and will mean that Roche and other sub-licensees will be able to work on pandemic orders within Africa.
08 May 2006 09:48:47
(Official Notice)
The board of directors of Aspen announced the resignation of Werner van Rensburg as executive director with effect from 8 May 2006.
27 Feb 2006 14:40:20
(Official Notice)
Aspen and Indian based Lupin Ltd have entered into a Memorandum of Understanding for the establishment of a 50:50 joint venture for the development, manufacture and global marketing of selected anti-tuberculosis (TB) products. The JV would also investigate opportunities to enter the Malaria market.
27 Feb 2006 13:07:48
(C)
The interim results are the company's first under International Financial Reporting Standards.



The company's results were underpinned by the good performance delivered by its South African operations. Revenue of R1.687 billion showed growth of 27% and operating profit of R474 million represented an increase of 34%. The group's performance was improved by a decrease in the effective tax rate from 33.3% to 29.7%. Headline earnings per share of 86.3c are up 45% on the comparable prior year interim performance of 59.4c, while basic earnings per share increased by 42.26% to 84.5c (59.4c).



Prospects

Growth in the use of generic medicines in the South African market as well as the performance of the new product launches are expected to be key drivers to Aspen's growth over the remainder of the financial year. Greater legislative certainty may also emerge during this period. The strong increase in sales of ARV products should continue, particularly in export markets, albeit at significantly lower margins to the rest of the business. Unlocking production capacity to match demand growth will remain a focus. Investments completed and currently under negotiation are planned to strategically position Aspen for continued growth. The joint ventures with Matrix and Lupin will help place Aspen as a leader in fighting infectious disease. The construction of the sterile manufacturing facility and the development of sterile products will create a domestic and international presence for Aspen in a specialist product area. Opportunities in existing and new territories continue to be evaluated for strategic fit with the group. It is anticipated that growth in HEPS for the full year will be significant, but the percentage growth for the second six months will not match that of the first six months.
23 Feb 2006 10:22:17
(Official Notice)
Pasco Dyani was appointed to the Aspen board with effect from 14 February 2006. Pasco is currently the National President and non-executive Chairperson of CEPPWAWU Investments (Pty) Ltd and CEPPWAWU Development Trust and a COSATU Central Executive Committee Member. CEPPWAWU Investments is Aspen's leading Black Economic Empowerment shareholder.
16 Feb 2006 09:02:17
(Official Notice)
Aspen has signed a non-exclusive license and technology transfer collaboration agreement with New York based Bristol-Myers Squibb for the manufacture and distribution of a generic version of Atazanavir, a new generation anti-retroviral. The royalty-free, perpetuity agreement provides for the manufacture and distribution of Aspen Atazanavir, a generic version of Atazanavir, to World Bank Tier 1 designated territories.
09 Feb 2006 17:04:27
(Official Notice)
Aspen anticipates that headline earnings per share and earnings per share for the six months ended 31 December 2005 (accounted for in terms IFRS) will exceed those of the restated previous interim period ended 31 December 2004 by between 40% and 45%. Headline earnings per share and earnings per share for the comparative period have been restated to comply with IFRS. Had Aspen continued to account for its results in terms of South African GAAP, headline earnings per share and earnings per share would have shown increases of a similar range on the reported results for the six months ended 31 December 2004. The conversion to IFRS has resulted in a reduction in headline earnings per share and earnings per share of between 6% and 8% for both the six month periods ended 31 December 2005 and 31 December 2004. Material items contributing to these reductions are: share-based payment expenses and amortisation on reinstatement of intangible assets previously written off.
09 Jan 2006 16:29:02
(Official Notice)
Aspen has announced the passing of Muzi Buthelezi in late December 2005. Muzi was appointed to the board of Aspen in February 2002 following the completion of the Black Economic Empowerment deal in terms of which CEPPWAWU Investments acquired a stake in Aspen.
07 Nov 2005 15:07:15
(Official Notice)
Aspen announced on 7 November 05 that its subsidiary company, Pharmacare Ltd, which trades as Aspen Pharmacare, has settled the long-running dispute with Tibbett - Britten Africa (Pty) Ltd (now owned by Exel plc which has previously been reported to shareholders. The Tibbett - Britten claim for R39 million in additional distribution fees has been withdrawn, and the previously reported contingent liability in this regard is therefore eliminated. In other agreements reached, Pharmacare has entered into a new five year arrangement with Exel subsidiary, Kinesis Logistics (Pty) Ltd for the performance of Pharmacare's fine distribution whilst Pharmacare will take control of its own bulk distribution which was previously performed by Exel.
26 Oct 2005 15:36:54
(Official Notice)
Shareholders are advised that, other than for the withdrawal of ordinary resolution number 9 relating to the general authority to issue shares for cash, all other resolutions were passed by the requisite majority of shareholders at the annual general meeting held on 26 October 2005.



Shareholders are reminded of the following salient dates in respect of the capital distribution of 48 cents per ordinary share:

Friday, 4 November 05 -- Last day to trade cum distribution:

Monday, 7 November 05 -- Trading commences ex distribution:

Friday, 11 November 05 -- Record date:

Monday, 14 November 05 -- Payment date:

Share certificates may not be dematerialised or rematerialised between Monday, 7 November 2005 and Friday, 11 November 2005, both days inclusive.

03 Oct 2005 14:14:13
(Official Notice)
The 2005 annual general meeting of shareholders of Aspen will be held in the boardroom, building number 8, Healthcare Park, Woodlands Drive, Woodmead on Wednesday, 26 October 2005 at 09:30
26 Sep 2005 12:14:22
(Official Notice)
Aspen and Lupin Ltd of India have entered into an agreement to collaborate in the tuberculosis (TB) related products market in South Africa. The agreement involves co-operation in the areas of technology, manufacture and marketing. Stephen Saad, Aspen Group Chief Executive said, `the agreement enhances South Africa and Aspen`s ability to respond to the growing TB pandemic that continues to affect all sectors of society. HIV and AIDS have substantially raised TB infection rates in South Africa, thereby placing immense pressure on the country`s healthcare resources. Aspen also previously received licenses for multi-drug resistant TB drugs from Eli Lilly. These combined deals complement Aspen`s strength in the TB environment. Consequently Aspen is the only pharmaceutical manufacturer in the country to offer both first and second line TB treatments and Aspen is the continent`s leader in providing pharmaceutical solutions for poverty-related diseases.`



The arrangement will leverage the Lupin`s technological expertise relating to cures for TB, as well as Aspen`s extensive marketing and technical capabilities. The current market size for TB medication in South Africa is estimated at approximately USD15m per annum. The agreement makes provision for milestone payments of up to USD2m from Aspen to Lupin based on achievement of key deliverables and a profit sharing arrangement. The agreement remains subject to the fulfilment of certain conditions precedent.

23 Sep 2005 09:04:09
(Official Notice)
Aspen has signed definitive joint venture (JV) agreements with Indian-based Matrix Laboratories Ltd (Matrix). The deals strengthen Aspen`s vertical integration into the manufacture of Active Pharmaceutical Ingredients (APIs), the key raw materials required in the manufacture of finished dosage form pharmaceuticals including anti-retrovirals (ARVs), and they unlock additional global supply and manufacturing opportunities.



The basis of the two JVs is:

*The sale of 50% of Aspen`s 100% ownership of Cape Town based Fine Chemicals Corporation (Pty) Ltd (FCC) to Matrix for a purchase consideration of USD20m. FCC is South Africa`s leading API manufacturer and a major exporter of product to the USA and other territories; and

*Aspen to acquire a 50% stake of a newly incorporated Indian company, Astrix Laboratories (`Astrix`), into which Matrix will transfer an API manufacturing facility, technology and intellectual property (IP) for a consideration of USD36.5m.



The Astrix facility, situated near Hyderabad, will be Aspen`s lead supplier of ARV APIs. Astrix will also continue supplying its existing customer base with ARV APIs. The site offers scope for modular expansion and in terms of the agreement Astrix may also source additional API volumes from other Matrix production facilities on a toll-manufacture basis. Approvals for the JVs are subject to approvals by, inter alia, the South African Reserve Bank, the Reserve Bank of India and South Africa`s competition authorities.
15 Sep 2005 15:25:35
(Media Comment)
Business Report on 15 September 05, noted that Funani, a small party in the Imithi consortium that had entered into a BEE deal with Aspen, expected Aspen to buy back it`s shares at 75% of market value if other parties to the contract were not interested in its shares. Aspen responded that they will not buy back these shares nor will they enter into any negotiations. Other parties to the consortium also sided with Aspen expressing their dissatisfaction pointing out that Funani is one small party in the scenario with an agenda of its own.

14 Sep 2005 12:38:37
(Media Comment)
A dispute between Aspen and Funani, a 1.8% stakeholder in the Imithi consortium who bought 10.4% of Aspen Pharamacare, attracted media attention this week. Many black empowerment deals contain lock-in clauses in which shares are offered to black investors at a discount, but then prevents them from selling it off before a certain period of time has passed. As noted in the Business Day of September 14 2005, Funani threatened to pull out of its deal with Aspen, mainly due to a shareholders` agreement preventing them from doing any business with any of Aspen`s competitors. According to Funani, business between the two companies was not as expected, therefore forcing them to look at other business partners. While Aspen had released Funani from the lock-in clause, the parties are still struggling to reach an agreement as to what price the BEE shares will be sold for, since none of the other members are willing to buy the shares at the price Funani are offering them at.

22 Aug 2005 14:05:05
(C)
The strong performance of the South Africa business dominated the group`s results. The acquisitions in July 2004 of Fine Chemicals Corporation (Pty) Ltd (`FCC`) and Nutricia (Pty) Ltd contributed towards revenue growth of 32%. The international businesses contributed R534 million to revenue, 19% of the group total. This is up 22% on the prior year. Aspen has recorded headline earnings per share of 144.7c (103.70c) for the year ended 30 June 2005, an increase of 40%. These excellent results were driven by a 30% rise in revenue to R2.9 billion (R2.2 billion) and a 32% increase in earnings before interest, taxation and amortisation (`EBITA`) to R831 million. Net profit to shareholders climbed to R494 million (R356 million). A dividend of 48cps has been declared.



Prospects

The group`s South African business has entered into an exciting phase of unprecedented new product launches. Aspen expects this activity will allow it to maintain its position as the leading provider of generic medicines in both the private and public sectors in the year ahead. Sales of ARVs are expected to grow materially as Aspen services the South African market and the PEPFAR territories. New products are also expected to provide additional impetus to Aspen`s growing consumer product portfolio. The accreditations received for the OSD facility have created a number of export manufacturing opportunities and has opened the way for the group to explore new markets.
27 Jul 2005 16:56:40
(Official Notice)
MSD and Aspen are pleased to announce that they are engaged in ongoing discussions relating to the formal licence agreement required by the non-binding Letter of Intent for MSD to grant Aspen a licence for efavirenz. It is anticipated that the formal agreement will be signed by 1 August 2005. Aspen intends to commence the testing and development of the product as soon as possible with a view to submitting a dossier for registration by the Medicines Control Council (`MCC`) in South Africa during the first quarter of 2006. Because of the nature of the product, Aspen intends to file for fast track approval with the MCC. Aspen has undertaken to contribute a percentage of its sales of efavirenz to the Msizi Trust, to be administered jointly by MSD and Aspen, to provide support to the management, treatment and care of people living with HIV/AIDS in South Africa.
21 Jul 2005 16:38:53
(Official Notice)
Aspen is expecting an increase of between 35% and 45% in earnings per share and between 30% and 40% in headline earnings per share for the year ended 30 June 2005 compared to those of the previous year. Headline earnings per share are adjusted to exclude the amortisation of goodwill. The anticipated higher percentage increase in earnings per share growth as compared with the percentage growth in headline earnings per share is mainly due to the adoption of accounting standard `IFRS3 (AC140) Business Combinations` for the year ended 30 June 2005. Consequently goodwill will not be amortised in Aspen`s results for the 2005 year. Aspen`s audited results for the year ended 30 June 2004 recorded goodwill amortisation of R13.8m. The financial results on which this trading statement has been based have not been reviewed or reported on by Aspen`s external auditors. The release of the final announcement of results for the year ended 30 June 2005 is expected to be published on or about 22 August 2005.
19 Jul 2005 09:59:44
(Official Notice)
Merck Sharp - Dohme (MSD) SA (a subsidiary of Merck - Co Inc) has granted a non-exclusive, royalty-free patent license for the manufacture and supply of a generic version of efavirenz, (one of MSD`s antiretrovirals (ARV`s)), used for the treatment of HIV/AIDS, to Aspen, Africa`s leading generics manufacturer.
15 Jul 2005 14:12:01
(Official Notice)
Aspen has appointed Dr Nobuhle Judith Dlamini to its board of directors with effect from 1 July 2005. She is a qualified medical doctor with corporate finance and business experience, who led the negotiating team for Imithi Investments ((Pty) Ltd (`Imithi`) in the Black Economic Empowerment transaction recently concluded between Aspen and Imithi.
15 Jun 2005 17:22:24
(Official Notice)
Further to the announcement dated 7 June 2005, shareholders are advised that the Order of Court sanctioning the scheme of arrangement in terms of the Companies Act, proposed by Aspen between itself, Pharmacare Ltd and the shareholders of Aspen (other than Pharmacare, Ceppwawu Pharmaceuticals Investments (Pty) Ltd, Ceppwawu Pharmaceuticals Investments 2 (Pty) Ltd, Imithi Investments (Pty) Ltd and the Industrial Development Corporation of South Africa Ltd), was registered by the Registrar of Companies. All conditions precedent have thus been fulfilled.

07 Jun 2005 17:01:47
(Official Notice)
Further to the announcement dated 30 May 2005, shareholders are advised that the scheme of arrangement (`the scheme`) in terms of section 311 of the Companies Act, 1973 (Act 61 of 1973), as amended, proposed by Aspen between itself, Pharmacare Ltd (`Pharmacare`) and the shareholders of Aspen (other than Pharmacare, Ceppwawu Pharmaceuticals Investments (Pty) Ltd, Ceppwawu Pharmaceuticals Investments 2 (Pty) Ltd, Imithi Investments (Pty) Ltd and the Industrial Development Corporation of South Africa Ltd), was sanctioned by the High Court of South Africa (Witwatersrand Local Division) on Tuesday, 7 June 2005. The only remaining condition precedent to the Imithi transaction and the scheme is the registration by the Registrar of Companies of the Order of Court sanctioning the scheme.
09-Feb-2017
(X)
Aspen is a global supplier and manufacturer of branded and generic pharmaceutical products as well?as infant nutritionals and consumer healthcare products in selected territories.


Send e-mail to for any enquiries or see Contact Details for phone numbers
Home   •   Terms & conditions   •   PAIA   •   Privacy Policy   •   Security Notice   •   Contact Details
Market Statistics are calculated by Sharenet and are therefore not the official JSE Market Statistics. The calculation/derivation may include underlying JSE data.
© 2017 SHARENET (PTY) Ltd, Cape Town, South Africa
Best in 800x600 with IE6 or Mozilla Firefox